Marquette University

e-Publications@Marquette
Dissertations (1934 -)

Dissertations, Theses, and Professional
Projects

Heart Rate Variability Biofeedback Training as an Intervention for
Chronic Pain
Annette Marie Wilson
Marquette University

Follow this and additional works at: https://epublications.marquette.edu/dissertations_mu
Part of the Health Psychology Commons, and the Pain Management Commons

Recommended Citation
Wilson, Annette Marie, "Heart Rate Variability Biofeedback Training as an Intervention for Chronic Pain"
(2017). Dissertations (1934 -). 739.
https://epublications.marquette.edu/dissertations_mu/739

HEART RATE VARIABILITY
BIOFEEDBACK TRAINING
AS AN INTERVENTION
FOR CHRONIC PAIN

by
Annette Marie Wilson, M.A.

A Dissertation submitted to the Faculty of the Graduate School,
Marquette University,
in Partial Fulfillment of the Requirements for
the Degree of Doctor of Philosophy

Milwaukee, Wisconsin
August 2017

ii
ABSTRACT
HEART RATE VARIABILITY
BIOFEEDBACK TRAINING
AS AN INTERVENTION
FOR CHRONIC PAIN
Annette Marie Wilson, M.A.
Marquette University, 2017

Millions of Americans suffer from chronic pain. Treatment costs are in the
billions and some patients still do not find relief. Current effectiveness research shows
positive results for biofeedback training as an intervention for headache and other types
of chronic pain. The present retrospective, archival study used patient information
(N=72) collected during a heart rate variability biofeedback training program to assess
treatment effectiveness among patients who experience chronic pain. More specifically,
the study was designed to examine six research questions focused on patient-reported
levels of pain and distress, as well as catastrophizing, depression, anxiety, and
somatization. It was hypothesized that after three sessions of biofeedback, the patient
scores on these six variables would decrease.
A significant reduction in self-reported pain and distress was found immediately
after the biofeedback session, however, pain and distress scores generally returned to the
pre-session baseline by the beginning of the next biofeedback session and the reductions
in pain and distress were not maintained between sessions revealing a “sawtooth” pattern.
On average, patients reported a decrease of more than one point on a numeric (0 to 10)
rating scale when rating their pain after the biofeedback training intervention (1.21 for
Session 1; 1.63 Session 2; and 1.50 for Session 3). There was a slightly greater reduction
in distress ratings than pain ratings after each session of biofeedback (i.e., distress ratings
decreased an average of 1.75 after Session 1, 1.67 after Session 2, and 1.74 after Session
3).
Of the four symptom measures (catastrophizing, depression, anxiety, and
somatization), a statistically significant reduction was found only in the case of
catastrophizing scores. When comparing Session 1 and Session 3 catastrophizing, the
scores decreased 3.14 points on average (SD = 7.63), t(69) = 3.45, p = .001.
Catastrophizing influences one’s beliefs about his or her ability to cope with pain and
how much it interferes with his or her life. This finding strengthens the existing research
literature that highlights the importance of targeting physical and psychological
symptoms when developing a comprehensive pain management plan.
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Chapter 1: Introduction
“But pain is perfect misery, the worst of evils, and, excessive,
overturns all patience (Milton, 1676, p.412-413).”

Misery is a word that is often used to describe the experience of pain. Miserable,
nagging pain will test even the most patient of patients. The Merriam-Webster dictionary
(2015) defines pain as “1. The physical feeling caused by disease, injury, or something
that hurts the body. 2. Mental or emotional suffering: sadness caused by some emotional
or mental problem. 3. Someone or something that causes trouble or makes you feel
annoyed or angry.” For centuries, the concept of pain has been associated with misery
and suffering. The experience of pain includes a physical sensation as well as an
emotional component sometimes described as suffering. The International Association
for the Study of Pain (IASP) Subcommittee on Taxonomy defines pain as “An unpleasant
sensory and emotional experience associated with actual or potential tissue damage, or
described in terms of such damage (IASP, 1994).” This description acknowledges the
complex interaction of the sensory and emotional characteristics of pain. Pain is
complicated and has a subjective nature. Although diagnostic tests to detect specific pain
conditions exist, the experience of pain is explained primarily through self-report. Pain
management treatment providers cannot rely solely on objective test results to understand
pain. A patient’s subjective, emotional experience should be considered when assessing
and treating chronic pain.
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The IASP definition also recognizes that pain is described in terms of damage,
whether or not actual tissue damage is present. Pain is typically related to tissue damage
but it is not always proportionate. Some patients report experiencing severe pain with
minimal observable tissue damage while other patients with extensive tissue injuries
report low levels of pain. Physical observations can be poor predictors of patient
reported pain ratings. Individual thresholds for pain and pain coping behaviors greatly
impact one’s experience of pain.
There are different types of pain (e.g., norceptive, neuropathic, etc.) that one can
experience. Pain can exist over the entire body or in specific locations. Headaches are a
common location for pain. The Merriam-Webster dictionary (2015) defines headache as
“an ache or pain in the head” or “a difficult or annoying situation or problem.” Many
people experience the second definition of headache in reaction to unreasonable time
frames, inconsiderate coworkers, or even obnoxious family members. Some people
experience these types of headaches daily. However, this review is going to focus on the
first definition of headache: “a pain in the head” as well as other types of pain.

Overview of Pain
Prevalence of Pain
Everyone has experienced pain at some time in life. For many people, aches and
pains come and go without causing significant distress or impairment in life functioning.
Unfortunately, millions of people suffer from chronic pain, some on a daily basis. In the
2012 National Health Interview Survey, 126.1 million adults in the United States reported
experiencing some pain in the 3 months prior to the survey. In addition, 25.3 million
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American adults (11.2%) reported experiencing pain daily and another 23.4 million
(10.3%) reported having a lot of pain (Nahin, 2015). Nahin (2015) designed a pain
coding system based on pain persistence (days with pain in the last 3 months) and
bothersomeness (little, a lot, somewhere in between). This system was used to group the
survey participants into five pain categories: Pain free, category 1 (low), category 2,
category 3, and category 4 (highest). Based on this pain coding system, it was estimated
that 14.4 million Americans (6.4%) were classified as category 4, the highest level of
pain. Another 25.4 million (11.3%) were classified as category 3 pain severity. This
means that close to 40 million American adults suffer from category 3 or 4 pain. Those
with category 3 or 4 pain were more likely to have worse health status, to use more health
care services, and experience more disability than those with less severe pain (Nahin,
2015). These astonishingly high prevalence rates suggest that chronic pain is very
common in the United States.
The National Health Interview Survey (2009) indicated that low back pain was
the most common type of pain (28%) reported by adults in the U.S. More Americans
reported having low back pain (64,810) than any cancer (18,648), diabetes (20,490),
ulcers (17,665), kidney disease (4,483), and liver disease (3,287) combined (64,573).
The second most common type of pain is severe headache or migraine pain (16%), then
neck pain (15%) and facial or jaw or pain (5%). In addition, more women than men
reported experiencing all 4 pain types overall.
The American Pain Foundation conducted the Voices of Chronic Pain Survey
(2006) in order to evaluate the impact of chronic pain. They focused specifically on the
patients’ sense of control over chronic pain and the impact it has on their quality of life.
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They interviewed 303 patients who were being treated by a physician for chronic pain. It
is important to note that all of the participants were using an opioid as part of their
treatment for chronic pain. A little over half (51%) of the patients surveyed reported
feeling like they had little or no control over their pain even though they had been
engaged in treatment. Approximately 60% of respondents reported experiencing
breakthrough pain one or more times daily, even with regular opioid treatment. Their
pain negatively affected their well-being and overall quality of life. Of the 303
respondents, approximately 59% felt that pain impacts their life enjoyment and 77%
reported having depressed feelings. Approximately 70% reported difficulty
concentrating and 74% reported a lack of energy related to their pain. Sleep disturbance
was especially common with 86% of patients reporting difficulty sleeping.
Costs Associated with Pain
As stated above, millions of people suffer from pain; it impacts their quality of
life and ability to function at home and at work. People who experience chronic pain
have difficulty maintaining productivity in the workplace due to absences or reduced
performance on the job related to pain. Stewart and colleagues (2003) measured lost
productive time using survey data from the American Productivity Audit. They
identified four common pain conditions: arthritis, back, headache, and other
musculoskeletal. Overall, approximately 13% of the total workforce reported a loss in
productive time during a 2-week period due to some type of pain. The most common
pain condition resulting in lost productive time was headache (5.4%), followed by back
pain (3.2%), arthritic pain (2.0%), and other musculoskeletal pain (2.0%). Interestingly,
over three quarters (76.6%) of the lost productive time was explained by reduced
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performance at work and not work absence. Even when pain sufferers stayed at work,
their performance was subpar.
In 2003, lost productive time had an estimated cost of $61.2 billion per year
(Stewart et al., 2003). Their calculations were based on lost productive time in paid
working hours and number of absences from work. In 2010, the American Academy of
Pain Medicine estimated a massive amount of $635 billion as the cost of pain by
combining lost wages, lost productivity, and medical care associated with pain
management and treatment. People who experience severe pain reported 5 more days of
absence from work per year than people with no pain (Institute of Medicine, 2011).
These absences (and resulting lost productivity) cost between $11.6 and $12.7 billion
annually (Institute of Medicine, 2011). In 2009, pain management/treatment accounted
for 14% of all Medicare costs at approximately $65.3 billion (Institute of Medicine,
2011). By and large, pain is a costly condition.
Importance of Research in Pain Management
Pain affects everyone, even those who are pain free. With millions of Americans
suffering from chronic pain, it is likely that most people are touched in some way by
pain, either as a sufferer themselves or by family, friends, coworkers, or others who
experience chronic pain. Even with regular treatment that costs billions of dollars
annually, the majority of those with chronic pain experience breakthrough pain daily
(60%) and feel depressed (77%) (American Pain Foundation, 2006). The current cost of
pain is massive and still millions suffer physically, mentally, and emotionally. Treatment
for pain will always have a cost, but there may be less expensive treatment options that
are effective in treating the physical and psychological effects of pain. Medical
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interventions such as intra-articular steroid injections, spinal cord stimulators, and nerve
ablation are used to treat the physical pain, while cognitive behavioral therapy, relaxation
therapy, and biofeedback are common psychosocial and behavioral approaches used in
pain psychology. The efficacy of biofeedback training has been examined extensively
with headache patients and has been shown to be highly effective in treating headaches
and migraines (Nestoriuc, Martin, & Andrasik, 2008a; Nestoriuc, Reif, & Martin, 2008b).
Biofeedback training can be combined with other types of interventions as part of a
comprehensive pain management plan as it appears to increase the effectiveness of other
treatments (Silberstein, 2000). More research is needed to study the effectiveness of
biofeedback training with other types of pain and pain conditions. Two pilot studies
(Hallman, Olsson, von Schéele, Melin, & Lyskoy, 2011; Hassett,et al., 2006) using heart
rate variability (HRV) biofeedback with two types of pain (chronic neck pain and
fibromyalgia) found significant patient improvement in functioning and mood. These
results are promising and suggest that biofeedback, specifically HRV biofeedback
training, can be effective with several different types of pain.

Organization of the Literature Review

The literature review found in Chapter 2 begins by defining chronic pain and
identifying different types of pain. Numerous pain conditions (e. g., complex regional
pain syndrome, fibromyalgia, Ehler’s Danlos syndrome, chronic pain syndrome, etc.) and
locations of pain in the body (e. g., low back, knee, shoulder, etc.) are seen in pain
management healthcare programs. Instead of focusing on each pain condition, the types
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of pain are explained. Different types of headaches are also described and criteria for
several headache diagnoses are included. This study used patient information from a
mindfulness-based heart rate variability biofeedback training program at a Midwest pain
management center. Other than members of the pain management team, the department
of neurology is one of the primary referral sources for the biofeedback program that was
examined in this study and many of the biofeedback patients experience headache.
Information specifically about headache diagnosis and treatment is more relevant to these
patients and that is why it is also included in the literature review.
The next section of the literature review discusses the psychological impact of
chronic pain. Several psychological factors, such as catastrophizing, pain anxiety and
fear, and pain coping strategies, are identified. Research findings on psychosocial factors
and adjustment to pain are described. Specifically, the effects of catastrophizing on pain
intensity and functioning are examined.
Behavioral treatment options for chronic pain and migraine headache are also
discussed in the literature review. Cognitive-behavioral therapy (CBT) for chronic pain
is examined as a psychosocial treatment approach and the components of CBT for
chronic pain are identified. Behavioral treatment options for migraine headache include
relaxation training, cognitive-behavioral therapy/stress management training, and
biofeedback training. Research literature on the effectiveness of CBT in pain
management is also described.
The effectiveness of biofeedback training with headache is supported through
research from two meta-analyses, the American Academy of Neurology’s evidence-based
guidelines, and a comprehensive efficacy review on the use of biofeedback training in the
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treatment of migraine and tension-type headache. However, the research literature on
biofeedback training with other types of chronic pain is lacking. Furthermore,
biofeedback technology is constantly advancing and as a result, there are several types of
biofeedback equipment available. Heart rate variability biofeedback is gaining popularity
and empirical support as a treatment approach for chronic pain. Pilot studies showed
patient improvement (or perceived improvement) after 10-sessions of HRV biofeedback
training with chronic neck pain (Hallman, et al., 2011) and with fibromyalgia (Hassett, et
al., 2006). These results are encouraging, but in order to evaluate the effectiveness of
HRV biofeedback training with several types of chronic pain, including headache, more
research is needed.

Overview of the Present Study
The purpose of this archival study is to evaluate the effects of a mindfulnessbased, HRV biofeedback training program with patients who experience chronic pain.
The biofeedback training program is part of a comprehensive treatment approach at a
Midwest pain management center. In order to track patient progress, specific
psychosocial factors (catastrophizing, depression, anxiety, and somatization) were
assessed throughout biofeedback training using the Pain Catastrophizing Scale (PCS),
Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-Item (GAD-7),
and Patient Health Questionnaire 15-Item (PHQ-15). In addition, patients were asked to
report their levels of pain and distress using a numeric (0 to 10) rating scale before and
after each biofeedback session. This archival study focused on patient report of two pain
factors (pain rating and distress rating), as well as four psychological variables
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(catastrophizing, depression, anxiety, and somatization). The primary research questions
of this study are identified in Table 1.1 below. Pre- and post-treatment scores were
compared to address these research questions. Post hoc analyses were performed to
examine differences in pain and distress ratings of groups based on the level of
symptomatology of the four psychological variables (catastrophizing, depression,
anxiety, somatization).

Table 1.1. Primary Research Questions
1. Does biofeedback training affect patient report of pain levels?
2. Does biofeedback training affect patient report of distress levels?
3. Does biofeedback training affect patient catastrophizing scores?
4. Does biofeedback training affect patient depression scores?
5. Does biofeedback training affect patient anxiety scores?
6. Does biofeedback training affect patient somatization scores?
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Chapter 2: Literature Review
“The greatest evil is physical pain.” (Saint Augustine, Soliloquies, I, 21.)
Defining Chronic Pain
When described in medical literature, pain is often described as either acute or
chronic. Acute pain can be mild and last only seconds or it may be severe and present for
months. However, acute pain usually lasts less than 6 months and resolves once the
underlying cause has been treated. For example, a broken bone may be quite painful
immediately after the initial injury but the pain resolves once the bone is healed.
Unrelieved acute pain can lead to chronic pain. Chronic pain can be divided into two
categories: cancer and non-cancer pain. Cancer pain has many causes including pain due
to the malignant tumor itself and cancer-associated symptoms and infections. Patients
with cancer can also experience pain due to diagnostic testing or treatment, such as
chemotherapy or radiation therapy, or patients may have coexisting painful conditions.
This literature review will focus on non-cancer, chronic pain.
The American Chronic Pain Association (ACPA) defines chronic or persistent
pain as “ongoing or recurrent pain, lasting beyond the usual course of acute illness or
injury for more than 3 to 6 months, and which adversely affects the individual’s wellbeing” (2014). Chronic pain is classified by pathophysiology based on the functional
changes that cause pain. There are five types of pain: nociceptive, neuropathic, mixed,
idiopathic, and psychogenic.
Nociceptive Pain
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Nociceptive pain is associated with ongoing tissue injury (ACPA, 2014).
Nociceptive pain is often the result of an injury such as a bone fracture, burn, or arthritis.
Nociceptors (specialized pain receptors) are activated and send an electrical signal up the
spinal cord to the brain, where the signal is processed as pain (Winterowd, 2003). With
nociceptive pain, there are no permanent changes in the central nervous system.
Nociceptive pain can be temporary or chronic. For example, a broken bone heals and the
electrical signal is no longer sent to the brain so the pain is temporary. Arthritic pain is a
condition that involves chronic nociceptive pain.
Neuropathic Pain
Neuropathic pain is the result of damage to the brain, spinal cord, or peripheral
nerves (ACPA, 2014). Neuropathic injury involves permanent changes in the central
nervous system or the peripheral nervous system (Winterowd, 2003). Neuropathic pain
can be sharp, shooting, burning, and intense. Diabetic neuropathy and complex regional
pain syndrome are common types of chronic neuropathic pain. “Patients with
neuropathic pain often present with sensory changes such as allodynia (i.e., pain due to a
stimulus that does not normally provoke pain, e.g., light touch), hyperalgesia (i.e., an
increased response to a stimulus that is normally painful, e.g., a pinprick), and
hyperpathia (i.e., a syndrome characterized by an abnormally painful reaction to a
stimulus, especially a repetitive stimulus, e.g., a repetitive pinpoint, as well as lowered
pain threshold)” (Winterowd, 2003). The wind blowing or a bed sheet rubbing can be a
painful experience for people with severe neuropathic pain. To a person without
neuropathic pain, stubbing a toe might create an acute sharp pain that quickly dissipates.
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Stubbing a toe with active neuropathic pain and hyperalgesia can be tremendously
painful.
Mixed Pain
Mixed pain has elements of both nociceptive and neuropathic pain (Winterowd,
2003). A good example of mixed pain is a low back injury with a herniated disc
(nociceptive), which compressed nerve roots (neuropathic) resulting in mixed pain. For
this type of injury, both types of pain should be assessed and treated.
Idiopathic Pain
Idiopathic pain can be defined as pain without an identifiable organic substrate.
Idiopathic or unspecified pain is pain without an underlying physical explanation
(Winterowd, 2003). Some believe idiopathic pain is actually neuropathic in nature while
others insist that it is psychogenic.
Psychogenic Pain
The final type of pain is psychogenic pain. Psychogenic pain describes a process
whereby pain is psychological in nature and there is no physical pathology as the source
of pain (Winterowd, 2003). Common symptoms of psychogenic pain are headaches,
muscle pains, back pain, and stomach pain. Psychogenic pain should be diagnosed only
after organic causes of pain are ruled out. Psychological factors can cause, increase, or
prolong pain (Cleveland Clinic, 2014). This type of pain is often associated with
somatoform disorders.
Flare-Up Pain
People with chronic pain can experience continuous pain as well as flare-up pain.
Pain that is present for half the day or more is considered continuous pain (ACPA, 2014).
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Continuous pain can be treated with a scheduled approach using time-released
medications and therapies aimed at long-term relief. Flare-up pain, also referred to as
break-through pain, is a temporary increase in pain in someone who has adequately
controlled baseline pain (ACPA, 2014). Flare-up pain can be caused by physical activity
such as bending, walking, or getting up from a chair. For some patients, involuntary
actions like coughing or sneezing can lead to flare-up pain. With some pain syndromes,
like fibromyalgia, flare-up pain may exist as a natural part in the course of the underlying
medical condition. Stress and anxiety can trigger flare-up pain. Also, changes in the
environment, especially the weather, can generate flare-up pain. Patients may experience
flare-up pain at the end of a scheduled dose of pain medication. Treatment for flare-up
pain can include pharmacological and/or non-pharmacological approaches. The use of
short-acting opioids is common, especially for patients who use opioids in long-term
management of pain. However, regular use of short-acting opioids for increased pain
may lead to flare-up pain and escalating drug use without providing substantial pain relief
or increased function (ACPA, 2014).

Types of Headache
“'Do I look very pale?' said Tweedledum, coming up to have his helmet tied on.
(He called it a helmet, though it certainly looked much more like a saucepan.)
'Well—yes—a little,' Alice replied gently.
'I'm very brave, generally,' he went on in a low voice: 'only to-day I happen to
have a headache.'” (Through the Looking Glass, Carroll, 1871, p. 41).
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A pounding headache can steal the bravery of even the most fearless. Headache
can be considered a common experience had by all. Everyone has had a headache at
some point in life. They can differ in intensity and duration, some lasting for days
without relief. Headaches can present in different locations on the head: in the front
and/or the back, on the left side, right side, or both sides. There are different types of
headache. The most common types of primary headaches are migraine, tension-type,
cluster, and chronic daily headache.
Migraine Headache
Migraine is an episodic, neurological disorder with headache attacks lasting from
4 hours to 72 hours, usually associated with nausea and/or light sensitivity (Cutrer &
Bajwa, 2015). Table 2.1 defines the diagnostic criteria for migraine without aura and
migraine with aura. Migraine without aura is also referred to as common migraine or
hemicrainia simplex (ICHD-3, 2013). The ICHD-3 identifies criteria for Pure Menstrual
Migraine and Menstrually related migraine, however some argue that it is not a separate
diagnosis. Migraine with aura is also called classic migraine, hemiparaesthetic,
hemiplegic or aphasic migraine, or complicated migraine (ICHD-3, 2013).
A typical migraine episode progresses through four phases: the prodrome, the
aura, the headache, and the postdrome. These phases are not required criteria for a
diagnosis of migraine and most people do not experience all four phases. Approximately
60% of migraineurs go through the prodrome phase, which occurs 24-48 hours prior to
the onset of headache (Kelman, 2004). Prodromal symptoms include euphoria,
depression, irritability, constipation, neck stiffness, and increased yawning (Cutrer &
Bajwa, 2015). Also, patients may experience food cravings during this initial phase.

15
Migraine aura is a focal neurological phenomenon that precedes or accompanies a
migraine attack (Cutrer & Bajwa, 2015). Typical migraine auras develop gradually and
usually last less than 60 minutes. Visual auras are the most common and can present as a
bright light or with vision loss. Over 90% of patients with migraine with aura experience
visual aura, at least with some headache attacks (ICHD-3, 2013). Sensory aura is the
second most common type of aura. It frequently comes after the visual aura but can also
occur alone. It typically starts as a tingling sensation, described as “pins and needles”, on
one side of the body, face, and/or tongue (ICHD-3, 2013). Olfactory hallucinations,
motor aura, dysphasic aura (language aura), and delusions/disturbed consciousness are
less common than visual and sensory auras. The headache phase can be experienced
simultaneously with aura. Migraine headaches are typically unilateral but can also be
bilateral. Patients report a throbbing or pulsating sensation, especially as the intensity
increases (Cutrer & Bajwa, 2015). An untreated migraine headache usually lasts
anywhere from 4 to 72 hours. Nausea, photophobia (sensitivity to light), and/or
phonophobia (sensitivity to sound) are commonly reported symptoms of migraine
headache. The final phase is migraine postdrome. Following the headache, patients
often feel exhausted or drained of energy. However, some patients report feeling
refreshed or euphoric (Cutrer & Bajwa, 2015). Patients experiencing migraine headache
symptoms on 15 or more days per month may consider a diagnosis of chronic migraine.
Migraine transformation is a process by which a patient’s episodic migraine pattern
transitions to a chronic migraine pattern (Cutrer & Bajwa, 2015).
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Table 2.1. Diagnostic Criteria for Migraine (ICHD-3: International Classification of
Headache Disorders, 3rd edition)
Migraine without Aura (“common migraine”)
A. At least 5 attacks fulfilling criteria B through D
B. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics:
1. Unilateral location
2. Pulsating quality
3. Moderate or severe pain intensity
4. Aggravation by or causing avoidance of routine physical activity (e.g., walking
or climbing stairs)
D. During headache at least one of the following:
1. Nausea, vomiting, or both
2. Photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis
Migraine with Aura (“classic migraine”)
A. At least 2 attacks fulfilling criterion B and C
B. One or more of the following fully reversible aura symptoms:
1. Visual
2. Sensory
3. Speech and/or language
4. Motor
5. Brainstem
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6. Retinal
C. At least two of the following four characteristics:
1. At least one aura symptom spreads gradually over ≥ 5 minutes, and/or two or
more symptoms occur in succession
2. Each individual aura symptom lasts 5 to 60 minutes
3. At least one aura symptom is unilateral
4. The aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD-3 diagnosis, and transient ischemic attack
(TIA) has been excluded

Tension-Type Headache (TTH)
Tension-type headache is the most prevalent type of headache in the general
population (ICHD-3, 2013). Table 2.2 describes the criteria for diagnosing TTH. The
intensity of a TTH attack is usually mild to moderate and the duration varies from person
to person (Taylor, 2014). This type of headache is typically bilateral and patients report
feeling pressure or tightness in the head (Taylor, 2014). Routine physical activity should
not aggravate the headache pain. TTH is not associated with nausea but patients may
report experiencing photophobia or phonophobia (Taylor, 2014). Stress and mental
tension are the most common precipitating factors with TTH (Spierings, Ranke, &
Honkoop, 2001). Some patients experience both migraine and tension-type headaches.
Migraine headache may precipitate or exacerbate TTH symptoms.
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Table 2.2. Diagnostic Criteria for Episodic Tension-Type Headache (ICHD-3:
International Classification of Headache Disorders, 3rd edition)
A. At least 10 episodes of headache fulfilling criteria B through D. Infrequent and
frequent episodic subforms of TTH are distinguished as follows:
1. Infrequent episodic TTH: Headache occurring on <1 day per month on average
(<12 days per year).
2. Frequent episodic TTH: Headache occurring on 1 to 14 days per month on
average for >3 months (≥12 and <180 days per year).
B. Headaches lasting from 30 minutes to 7 days.
C. At least two of the following four characteristics:
1. Bilateral location
2. Pressing or tightening (nonpulsating) quality
3. Mild or moderate intensity
4. Not aggravated by routine physical activity (e.g., walking or climbing stairs)
D. Both of the following:
1. No nausea or vomiting
2. No more than one of photophobia or phonophobia
E. Not better accounted for by another ICHD-3 diagnosis

Cluster Headache
Cluster headache is the most common type of trigeminal autonomic cephalalgias
(TACs) (May, 2014). Table 3 identifies the diagnostic criteria for cluster headache.
Cluster headaches are strictly unilateral and the symptoms remain on one side of the head
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during a single cluster attack (May, 2014). Sometimes symptoms can switch to the other
side during a different cluster attack. Cluster headache is characterized by “attacks of
severe orbital, supraorbital, or temporal pain, accompanied by autonomic phenomena
and/or restless or agitation (ICHD-3, 2013). Patients with cluster headache describe the
pain as deep, continuous, excruciating, and explosive (May, 2014). A cluster attack
usually lasts between 30 minutes and 3 hours.

Table 2.3. Diagnostic Criteria for Cluster Headache (ICHD-3: International
Classification of Headache Disorders, 3rd edition)
Cluster Headache
A. At least 5 attacks fulfilling criteria B through D
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 to
180 minutes when untreated; during part (but less than half) of the time-course of cluster
headache, attacks may be less severe and/or of shorter or longer duration
C. Either or both of the following:
1. At least one of the following symptoms or signs ipsilateral to the headache:
a. Conjunctival injection or lacrimation
b. Nasal congestion and/or rhinorrhea
c. Eyelid edema
d. Forehead and facial sweating
e. Forehead and facial flushing
f. Sensation of fullness in the ear
g. Miosis and/or ptosis
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2. A sense of restlessness or agitation
D. Attacks have a frequency between 1 every other day and 8 per day for more than half
the time when the disorder is active
E. Not better accounted for by another ICHD-3 diagnosis
Episodic Cluster Headache
A. Attacks fulfilling criteria for cluster headache and occurring in bouts (cluster periods)
B. At least 2 cluster periods lasting from 7 days to 1 year (when untreated) and separated
by pain-free remission periods of 1 month or more
Chronic Cluster Headache
A. Attacks fulfilling criteria for cluster headache
B. Attacks occurring without a remission period, or with remissions lasting less than 1
month, for at least 1 year

Chronic Daily Headache
Chronic daily headache (CDH) is a syndrome that encompasses primary and
secondary headache subtypes. The term CDH includes several subtypes of frequent
headaches grouped according to duration (Garza & Schwedt, 2015). Headaches lasting
four hours or more are considered long duration. The primary chronic daily headache
subtypes of long duration include chronic migraine, chronic tension-type headache,
medication overuse headache, hemicranias continua, and new daily persistent headache
(Garza & Schwedt, 2015). These types of headaches are prolonged headaches lasting
four hours or longer. The term primary CDH refers to headaches with frequency of 15 or
more days per month for longer than three months (Dodick, 2006).
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Chronic Migraine. Chronic migraine is a “headache occurring on 15 or more
days per month for more than three months, which has the features of migraine headache
on at least eight days per month” (ICHD-3, 2013). These headaches are present daily or
near daily. Some headaches may be rated as low or moderate intensity with mild
migrainous features. Patients may also experience severely intense headaches with more
prominent migraine symptoms (Garza & Schwedt, 2015).

Table 2.4. Diagnostic Criteria for Chronic Migraine (ICHD-3: International
Classification of Headache Disorders, 3rd edition)
A. Headache (tension-type-like and/or migraine-like) on 15 or more days per month for
more than 3 months and fulfilling criteria B and C
B. Occurring in a patient who has had at least 5 attacks fulfilling the following criteria
for migraine without aura (B1) and/or migraine with aura (B2)
B1. Migraine without aura:
B1a. Headache attacks lasting 4 to 72 hours (untreated or unsuccessfully treated)
B1b. Headache has at least two of the following characteristics:
i. Unilateral location
ii. Pulsating quality
iii. Moderate or severe pain intensity
iv. Aggravation by or causing avoidance of routine physical activity (e.g.,
walking or climbing stairs)
B1c. During headache at least one of the following:
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i. Nausea and/or vomiting
ii. Photophobia and phonophobia
B2. Migraine with aura
B2a. One or more of the following fully reversible aura symptoms:
i. Visual
ii. Sensory
iii. Speech and/or language
iv. Motor
v. Brainstem
vi. Retinal
B2b. At least two of the following characteristics:
i. At least one aura symptom spreads gradually over ≥5 minutes, and/or two or
more symptoms occur in succession
ii. Each individual aura symptom lasts 5 to 60 minutes
iii. At least one aura symptom is unilateral
iv. The aura is accompanied, or followed within 60 minutes, by headache
C. On 8 days or more per month for more than 3 months, fulfilling any of the following:
1. Criteria B1b and B1c for migraine without aura
2. Criteria B2a and B2b for migraine with aura
3. Believed by the patient to be migraine at onset and relieved by a triptan or ergot
derivative
D. Not better accounted for by another ICHD-3 diagnosis
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Chronic Tension-Type Headache. This diagnosis is for people who have daily or
very frequent episodes of tension-type headache. These headaches are typically bilateral
and pressing or tightening in quality (Garza & Schwedt, 2015). Usually they are mild to
moderate intensity and last hours to days without relief. Routine physical activity should
not aggravate the pain. However, patients may report having mild nausea, photophobia,
phonophobia, or muscle tenderness (Garza & Schwedt, 2015).

Table 2.5. Diagnostic Criteria for Chronic Tension-Type Headache (ICHD-3:
International Classification of Headache Disorders, 3rd edition)
A. Headache occurring on ≥15 days per month on average for more than 3 months (≥180
days per year) and fulfilling criteria B through D
B. Lasting hours to days, or unremitting
C. At least two of the following characteristics:
1. Bilateral location
2. Pressing or tightening (non-pulsating) quality
3. Mild or moderate intensity
4. Not aggravated by routine physical activity (e.g., walking or climbing stairs)
D. Both of the following:
1. No more than one of photophobia, phonophobia, or mild nausea
2. Neither moderate or severe nausea nor vomiting
E. Not better accounted for by another ICHD-3 diagnosis
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Medication Overuse Headache. These headaches have been called by several
different names over the years: analgesic rebound headache, drug-induced headache, and
medication-misuse headache. Currently, the term is medication overuse headache
(MOH). These headaches develop as a consequence of regular overuse of acute or
symptomatic headache medication. Typically, patients have an episodic headache
disorder diagnosis like migraine or tension-type headache, and have been treated with
large doses of acute medications (Garza & Schwedt, 2015). Medication overuse
headache presents as a consequence of excessive medication use for more than 3 months.
This type of headache usually resolves after overuse of medication is discontinued (Garza
& Schwedt, 2015).

Table 2.6. Diagnostic Criteria for Medication Overuse Headache (ICHD-3:
International Classification of Headache Disorders, 3rd edition)
A. Headache occurring on 15 or more days per month in a patient with a pre-existing
headache disorder
B. Regular overuse for more than 3 months of one or more drugs that can be taken for
acute and/or symptomatic treatment of headache:
1. Regular intake for ≥10 days per month for >3 months of ergotamines, triptans,
opioids, or combination analgesics, or any combination of ergotamines, triptans, simple
analgesics, NSAIDs and/or opioids without overuse of any single drug or drug class alone
or when the pattern of overuse cannot be reliably established.
2. Regular intake for ≥15 days per month for >3 months of simple analgesics (ie,
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acetaminophen, aspirin, or NSAID).
C. Not better accounted for by another ICHD-3 diagnosis.

Hemicranias Continua. This type of persistent headache is strictly unilateral but
has autonomic features ipsilateral to the side of pain (Garza & Schwedt, 2015). These
features include conjunctival injection, lacrimation, nasal congestion, rhinorrhea,
forehead and facial sweating, miosis, ptosis and/or eyelid edema, and/or with restlessness
or agitation (ICHD-3, 2013). For a diagnosis of hemicranias continua, headache must be
present for more than 3 months, unremitting without pain-free intervals. Intensity can
vary with exacerbations of moderate or severe intensity. This type of headache responds
well to therapeutic doses of indomethacin (ICHD-3, 2013).

Table 2.7. Diagnostic Criteria for Hemicranias Continua (ICHD-3: International
Classification of Headache Disorders, 3rd edition)
A. Unilateral headache fulfilling criteria B to D
B. Present for more than 3 months, with exacerbations of moderate or greater intensity
C. Either or both of the following:
1. At least one of the following symptoms or signs, ipsilateral to the headache:
a. Conjunctival injection and/or lacrimation
b. Nasal congestion and/or rhinorrhea
c. Eyelid edema
d. Forehead and facial sweating
e. Forehead and facial flushing
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f. Sensation of fullness in the ear
g. Miosis and/or ptosis
2. A sense of restlessness or agitation, or aggravation of the pain by movement
D. Responds absolutely to therapeutic doses of indomethacin
E. Not better accounted for by another ICHD-3 diagnosis

New Daily Persistent Headache. This type of headache is present daily from its
onset (ICHD-3, 2013). The onset is sudden so patients can usually remember when their
headache started (Garza & Schwedt, 2015). The pain is usually bilateral but it lacks other
characteristic features. These headaches can present with migrainous and/or tension-type
headache symptoms (Garza & Schwedt, 2015).

Table 2.8. Diagnostic Criteria for New Daily Persistent Headache (ICHD-3:
International Classification of Headache Disorders, 3rd edition)
A. Persistent headache fulfilling criteria B and C
B. Distinct and clearly remembered onset, with pain becoming continuous and
unremitting within 24 hours
C. Present for more than 3 months
D. Not better accounted for by another ICHD-3 diagnosis

Psychological Factors and Chronic Pain
Keefe and colleagues (2004) identified two categories of psychological factors
that can affect one’s adjustment to chronic pain. The first category is associated with
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increased pain, psychological distress, and physical disability. It includes psychological
factors such as pain catastrophizing, pain-related anxiety and fear, and helplessness. The
second category is made up of psychological factors correlated with decreased pain,
distress, and physical disability. Self-efficacy, pain coping strategies, readiness to
change, and acceptance are included in the second category.
Pain Catastrophizing
The concept of “catastrophizing” and its influence on pain perception has been
extensively examined in pain management research. Catastrophizing is described as a
maladaptive coping strategy that intensifies the experience of pain and depression (Keefe,
Brown, Wallstrom, & Caldwell, 1989). Catastrophizing is a cognitive process that leads
to the expectation of a negative outcome. Keefe and colleagues (1989) posit that
catastrophizing can explain variations in pain and depression in chronic pain patients.
They found that catastrophizing is positively correlated with depression (Keefe et al.,
1989; Rosenstiel & Keefe, 1983). Catastrophizing involves a negative evaluation of
one’s ability to cope with changes in pain and negative pain-related cognitions.
Catastrophizing is a strong predictor of dysfunctional pain beliefs and behaviors (Keefe,
Rumble, Scipio, Giordano, & Perri, 2004). Automatic thoughts and acquired belief
systems about pain can be influenced by catastrophizing. One of the most common
instruments used to assess catastrophizing is the Pain Catastrophizing Scale (PCS;
Sullivan, Bishop, & Privik, 1995). This 13-item instrument has 3 subscales:
magnification, rumination, and helplessness.
Pain Related Anxiety and Fear
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Patients with chronic pain can have anxiety and fear associated with pain and may
engage in fear avoidance behaviors. “Pain-related anxiety and fear are important
predictors for how patients adapt to pain” (Vlaeyen & Linton, 2000). Research has
shown that patients who report high levels of pain-related anxiety have a high attentional
awareness of pain sensations (McCracken, 1997). Also, patients with high levels of
anxiety and fear related to pain, seek medical treatment frequently (McCracken, 1998).
Research has found a strong connection between fear of pain and adjustment to pain.
Fear of movement can foster pain avoidance behaviors and functional disability. Using
615 patients with acute low back pain, Swinkels-Meewisse and colleagues (2003)
examined how fear affected one’s pain experience. Data analyses found that patients
who reported high levels of pain-related fear were significantly more likely to experience
high levels of disability and avoid participating in work and leisure activities (SwinkelsMeewisse et al., 2003).
Helplessness
Helplessness is a major factor in adjustment to pain. Adapted from learned
helplessness theory, Nicassio and colleagues (1999) describe a model to understand
helplessness with chronic pain. The model identifies helplessness and perceived patient
control as mediators in patient well-being. They studied this model using 122 patients
with fibromyalgia and found some interesting results. Helplessness partially mediated
the effects of pain and disability of depression, and fully mediated the effects of pain on
self-reported pain behaviors. This suggests that pain and disability can affect mood
disturbance and pain behaviors through helplessness.
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Self-Efficacy
The concept of self-efficacy was developed from Bandura’s social-cognitive
theory. Perceived self-efficacy refers to “people’s judgment of their capabilities to
organize and execute courses of action required to attain designated types of
performance” (Bandura, 1997). Self-efficacy has more to do with one’s perceived ability
to perform a task than one’s actual ability. How one judges his or her abilities influences
self-efficacy. Self-efficacy focuses on patient strengths versus weaknesses.
Understanding how to enhance self-efficacy is an important piece in treatment for chronic
pain. Self-efficacy studies have revealed that patients vary greatly in terms of selfefficacy. Studies also show that higher levels of self-efficacy have lower levels of pain,
report less psychological distress, and better medical outcomes (Brekke, Hiortdahl, &
Kvien, 2003; Keefe et al., 2002; 2004).
Brekke and colleagues (2003) conducted a longitudinal study investigating
changes in self-efficacy in 306 patients with rheumatoid arthritis over a 5-year period.
Overall, they found a correlation between changes in self-efficacy and changes in health
status. High baseline levels of self-efficacy were positively correlated with improvement
in pain measures. They concluded that baseline self-efficacy levels influence future
perceived pain levels.
Pain Coping Strategies
Pain coping strategies include cognitions and behaviors that decrease distress
associated with pain. Cognitive coping includes positive core beliefs and cognitions
focused on acceptance rather than cure. Patients also engage in behaviors (e.g.,
diaphragmatic breathing) that help them cope with the experience of chronic pain. In
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chronic pain management, coping encompasses all patient efforts to deal with the
physical, emotional, and behavioral consequences of pain. Each of these aspects of pain
may require different coping techniques. Coping is a constant process when living with
chronic pain. Coping involves stress management and adapting to pain. When used
effectively, pain coping strategies can decrease the negative impact of pain.
Readiness to Change
It is important to assess a patient’s readiness to change during treatment. The
Stages of Change model (Prochaska & DiClemente, 1992) can be used when exploring a
patient’s readiness to change. A patient can be in one of the five stages of change: (1)
precontemplation, not intending to change; (2) contemplation, intending to change in the
foreseeable future; (3) preparation, intending to change in the immediate future; (4)
action, making efforts to change; or (5) maintenance, working to maintain changes.
The Multidimensional Pain Readiness to Change Questionnaire-2 (MPRCQ2) has
been developed to measure patient readiness to adopt several coping strategies and pain
management approaches (Nielson et al., 2008). Clinical samples included patients with
fibromyalgia (n=139), arthritis (n=51), spinal cord injury pain (n=127), and amputation
pain (n=120). The MPRCQ-2 is useful for assessing patient readiness to change several
pain-related coping behaviors.
Acceptance
Pain acceptance is observed when a patient is willing to engage in meaningful life
activities regardless of the negative physical and emotional aspects of pain (Keefe et al.,
2004). The concept of acceptance is useful in the management of chronic pain. It is a
dynamic process where patients can move within. Acceptance of pain is related to
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improved adjustment to chronic pain (McCracken, 1998). Acceptance studies have
shown that high scores on acceptance measures like the Chronic Pain Acceptance
Questionnaire (CPAQ) are associated with lower levels of pain-related anxiety and
avoidance, depression, and physical and psychosocial disability (McCracken, 1998).

Research on Psychological Factors and Adjustment to Pain
In a systematic review, Jensen and colleagues (2011) examined the research
literature regarding associations between psychological factors and adjustment to pain.
Their multivariate regression analyses found that psychosocial factors as a group account
for a significant amount of variance in the prediction of pain, physical functioning, and
psychological functioning. Six of the studies reviewed by Jensen (2011) reported effect
sizes for predicting pain severity or intensity (Douglas, Wollin, & Windsor, 2008; Hill,
1993; Hill, Niven, & Knussen, 1995; Jensen et al., 2002; Osborne, Jensen, Ehde, Hanley,
& Kraft, 2007; Turner, Jensen, Warms, & Cardenas, 2002). The reported R^2 values had
a median of .27 (medium effect size) ranging from .19 (moderate effect size) to .43 (large
effect size). Effect sizes for the prediction of physical functioning were reported by
fourteen studies (Douglas et al., 2008; Engel, Jensen, & Schwartz, 2006; Engel,
Schwartz, Jensen, & Johnson, 2000; Hanley et al., 2004; Hill, Niven, & Knussen, 1995;
Jensen et al., 2002; Miro et al., 2009; Molton, Stoelb, & Jensen, 2009; Osborne et al.,
2007; Raichle, Hanlet, Jensen, & Cardenas, 2007; Stroud, Turner, Jensen, & Cardenas,
2006; Turner, Jensen, Warms, & Cardenas, 2002; Williams et al., 2004; Wollaars, Post,
van Asbeck, Floris, & Brand, 2007). The R^2 values reported had a median of .16
(medium effect size) ranging from .06 (small effect size) to .31 (medium effect size).
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Fifteen studies reported effect sizes associated with predicting psychological functioning
(Douglas, Wollin, & Windsor, 2008; Engel et al., 2006; Engel et al., 2000; Hanley et al.,
2004; Hill, 1993; Hill, Niven, & Knussen, 1995; Jensen et al., 2002; Miro et al., 2009;
Molton, Stoelb, & Jensen, 2009; Osborne et al., 2007; Raichle et al., 2007; Stroud et al,
2006; Turner et al., 2002; Williams et al., 2004; Wollaars et al., 2007). The median was
.31 (medium effect size) ranging from .07 (small effect size) to .58 (large effect size).
These effect sizes are generally substantial and emphasize the impact that psychosocial
factors as a whole have on pain and functioning.
In the same systematic review (Jensen et al., 2011) specific psychosocial factors,
such as catastrophizing, were examined. They found that catastrophizing in itself was
significantly correlated with measures of pain and functioning. After reviewing the
current research literature, Jensen and colleagues (2011) concluded that catastrophizing
has moderate to strong associations with pain, physical functioning, and psychological
functioning. The correlation coefficients between catastrophizing and measures of pain
ranged from .14 (weak correlation) to .68 (strong correlation) with a median of .35 (weak
correlation) (Giardino, Jensen, Turner, Ehde, & Cardenas, 2003; Hill, 1993; Osborne et
al., 2007; Perry, Nicholas, & Middleton, 2009a; Perry, Nicholas, & Middleton, 2009b,
Ullrich, Jensen, Loeser, & Cardenas, 2007; Ullrich, Jensen, Loeser, Cardenas, & Weaver,
2008). Catastrophizing and physical functioning had a median correlation coefficient of
.44 (moderate correlation) ranging from .19 (weak correlation) to .67 (strong correlation).
(Miro et al., 2009; Molton, Stoelb, & Jensen, 2009; Osborne et al., 2007; Perry, Nicholas,
& Middleton, 2009a; Perry, Nicholas, & Middleton, 2009b; Raichle et al., 2007; Ullrich
et al., 2007; Ullrich et al., 2008; Wollaars et al., 2007). The correlation coefficients
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between catastrophizing and psychological functioning ranged from .23 (weak
correlation) to .64 (strong correlation) with a median of .53 (strong correlation).
(Giardino et al., 2003; Hill, 1993; Miro et al., 2009; Molton, Stoelb, & Jensen, 2009;
Osborne et al., 2007; Perry, Nicholas, & Middleton, 2009a; Perry, Nicholas, &
Middleton, 2009b; Raichle et al., 2007; Ullrich et al., 2007; Ullrich et al., 2008; Wollaars
et al., 2007). These moderate to strong correlations highlight the influence that
catastrophizing can have not only on pain severity, but also physical and psychological
functioning.

Treatment Options for Chronic Pain Management
Treatment for chronic pain can be complex and challenging. Several factors
should be considered when choosing the appropriate treatment approach and modality for
a patient with chronic pain. Warfield and Fausett (2002) identified multiple factors that
influence treatment approach: the source, character, location, and duration of pain as well
as the general condition of the patient being treated. Risks and benefits of any treatment
should be discussed with the patient. There are two main categories of treatment for
chronic pain: medical and behavioral.
Medical treatment options for chronic pain include injection therapies, invasive
procedures, physical measures, and pharmacological interventions. Opioids, non-opioids,
anti-inflammatory analgesics, and other medications like psychotropic drugs are classes
of medications used to treat chronic pain disorders. Trigger point injections, epiduralsteroid injections, facet injections, and nerve blocks are used to treat localized pain.
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Physical therapy, acupuncture, and massage are used to help chronic pain patients
function at their optimal level and alleviate movement dysfunction.
A wide range of surgeries, injections, and procedures are used as interventional
therapies in the treatment and management of chronic pain. Field states, “The goal of
many interventional therapies, including most surgical procedures, is to correct, or at
least modify, specific anatomic abnormalities, which were causing the pain. Other
interventional therapies, such as localized injections, are not designed to cure the
underlying disease, but instead to decrease the neural transmission of pain signals (Field,
2008, p. 57).” These interventions are used to manage pain exacerbation and provide a
period of temporary pain relief.
Invasive Interventions for Chronic Pain
Intra-Articular Steroid Injections. Intra-articular steroid injections are used in
the treatment of osteoarthritic joint pain. Intra-articular steroids are most effective for
short-term (1 to 3 weeks) pain relief but are not as effective for long-term pain relief
(ACPA, 2014). Viscosupplementation can be used to treat knee pain from osteoarthritis.
A lubricating substance (hyaluronic and hylan derivitatives) is injected into the knee joint
to lubricate movement, which decreases pain and improves mobility.
Viscosupplementation is also effective for short-term pain treatment and can provide a
more prolonged effect of pain relief than intra-articular steroids (ACPA, 2014).
Epidural Steroid Injections. Epidural steroid injections can be used to treat pain
associated with herniated discs, degenerative disc disease, or spinal stenosis with nerve
pain (ACPA, 2014). Steroids, sometimes combined with a local anesthetic, are injected
into the epidural space in the cervical spine (neck) or lumbar spine (low back). Steroids
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reduce inflammation and compression of the spinal nerve roots and adjacent tissues and,
therefore, decrease pain and improve mobility. Epidurals are most effective in treating
acute nerve pain and flare-up pain with chronic pain conditions. “These injections have
not been demonstrated to provide long-term successful pain relief for patients solely
suffering from chronic (long-standing) back pain or chronic nerve pain (ACPA, 2014).”
Patients who do not experience any pain relief from the first injection are unlikely to
benefit from more injections. Side effects from injections may occur, including
osteoporosis (weakening of the bones) and avascular necrosis (bone cell death often seen
in the hip) (ACPA, 2014). Patients may be able to avoid these side effects by limiting
the number of epidural steroid injection treatments per year.
Spinal Cord Stimulator. A spinal cord stimulator (SCS) delivers
neurostimulation therapy by generating mild electrical signals to the spinal area (ACPA,
2014). Spinal cord stimulators are implanted under the skin, typically in the abdomen
area, and can be programmed with the use of a remote control. Patients can adjust the
level of stimulation to match their activity level or in response to flare-up pain. Before a
SCS is implanted, there is a trial phase when one or two leads are positioned to assess
whether the patient experiences paresthesia (tingling sensation) in the painful area. After
the trial phase, the physician and patient can decide if it would be beneficial to advance to
permanent implantation. Prior to the trial and implantation of a SCS, it is common for
patients to have a psychological evaluation to determine if there are any emotional issues
or secondary gains that may negatively affect the surgery or recovery process and to also
ensure the patient has realistic expectations of the SCS. Spinal cord stimulation is
“primarily suited to certain neuropathic and ischemic (loss of oxygenated blood flow)

36
pain states (ACPA, 2014).” Spinal cord stimulation has been proven to be effective in
treating pain associated with failed back surgery syndrome with radicular symptoms,
complex regional pain syndrome, peripheral neuropathic pain, peripheral vascular
disease, and ischemic heart disease (ACPA, 2014).
Intrathecal Drug Delivery. Implanted targeted intrathecal drug delivery systems
(pain pumps) release pain medication directly into the sheath surrounding the spinal cord
(ACPA, 2014). Like a spinal cord stimulator, a programmable pain pump is surgically
implanted under the skin. Because the medication is directly delivered to the fluid
around the spinal cord, it may lead to fewer side effects (ACPA, 2014). Pain pumps are
used with patients who find oral opioids beneficial but cannot tolerate the side effects and
after trials of less invasive methods have failed. Similar to the evaluation process for a
SCS, patients usually have a psychological evaluation prior to the trial of a pain pump.
Intrathecal Drug Delivery has been approved by the FDA and has been shown to be an
effective pain therapy for patients who have not had success with other pain management
treatments (ACPA, 2014). Intrathecal therapy has been successful in pain management
for patients with failed back surgery syndrome, complex regional pain syndrome, spinal
stenosis, osteoporosis with compression fractures, pancreatitis, phantom limb pain
syndrome, and peripheral neuropathies (ACPA, 2014). The FDA has approved
ziconotide, morphine, and baclofen for continuous use through intraspinal infusion
(ACPA, 2014). Opioids (e.g., morphine) are the most common medications used in
implanted intrathecal delivery devices.
Nerve Blocks. “Nerve and facet blocks use a combination of local anesthetic and
steroid for diagnostic purposes to identify pain generators. These blocks can also be used
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therapeutically to “block” a painful condition (ACPA, 2014).” Nerve blocks are most
beneficial for short-term pain relief and can be used to relieve discomfort when combined
with an active rehabilitation program.
Radiofrequency Ablation. Radiofrequency ablation (rhizotomy) or lesioning
destroys the nerves that transmit pain signals to facet joints. “The facet joint, a small
joint that connects the back portion of your spine, can become arthritic and cause neck or
back pain (ACPA, 2014).” Medial branch blocks are used in determining the origin of
neck or back pain. Local anesthetic is injected into the nerves that are connected to the
facet joint. Based on the patient’s response to this block, he or she can be approved as a
candidate for medical branch radiofrequency ablation (rhizotomy). Radiofrequency
ablation usually blocks the signal for a prolonged period of time (six months to a year).
Eventually, the nerve grows back and can allow the pain signal to be transmitted again.
If this happens, the procedure can be repeated. This procedure often does not relieve all
back pain, but it relieves the pain associated with facet joint arthritis. With rhizotomies,
there is denervation of the spinal muscles with these procedures and thus repeated
rhizotomies can cause atrophy of these muscles (ACPA, 2014).
Acupuncture. Acupuncture is often used as complementary treatment in pain
management. Acupuncture is based on the concept that medical issues are due to
imbalances in the body’s flow of energy or “qi”. Energy flow pathways are connected by
more than 2000 acupuncture points throughout the body (Field, 2008). Needles are
inserted into these points in order to release blocked energy flow and restore balance.
From a Western medicine perspective, acupuncture is believed to release biochemicals
such as endorphins, neurotransmitters, and neurohormones (Field, 2008).
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Massage Therapy. Several massage therapy techniques can be used to treat
different types of pain. Sports massage therapy focuses on muscle tissue and can be used
to decease the chances of injury and enhance recovery post injury. Trigger point massage
applies pressure to small muscle spasms that can develop following an injury. Shiatsu
massage focuses on “energy points” and “energy lines” in the body (Field, 2008).
Swedish massage therapy uses light pressure to relax muscles. Swedish massage can also
improve circulation, stimulate the skin, and increase the suppleness of tendons and
ligaments (Field, 2008).
Physical Therapy. In pain management, the goals of physical therapy should be
to improve strength, flexibility, and endurance without exacerbating pain (Field, 2008).
Exercise and movement are often avoided by people with chronic pain because it can
make the pain worse. At the same time, a lack of exercise can cause deconditioning and
also worsen pain, “Physical inactivity can cause significant loss of muscle tone, and as
the muscles become deconditioned, exercise (and even movement) becomes increasingly
painful. Deconditioning also affects cardiovascular fitness such that the heart works less
efficiently, leading to fatigue and decreased endurance (Field, p. 83).” A physical
therapist can customize a treatment plan based on the patient’s individual needs. Physical
therapy can be a painful journey. Patients should be encouraged to distinguish “good
pain,” i.e., harmless pain associated with building muscle, from “bad pain” or exercise
that seriously exacerbates the underlying painful condition.
Physical therapy exercises may aggravate painful areas and become sore temporarily.
The post-physical therapy soreness can be an uncomfortable side effect of a pain
management program focused on long-term outcomes.
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Transcutaneous Electrical Nerve Stimulation. The use of Transcutaneous
Electrical Nerve Stimulation (TENS) units is common with physical therapists. TENS
units use pulses of electricity to stimulate painful areas. TENS units are small and
portable and can be programed by the patient. The theory of pain relief behind
transcutaneous electrical nerve stimulation is that by stimulating myelinated nerve fibers,
it inhibits the transmission of pain signals along unmylenated C fibers (Field, 2008).
Pharmacological Interventions for Chronic Pain
The American Chronic Pain Association (2014) identifies four major classes of
medications used in the treatment and management of chronic pain: Non-opioids,
opioids, adjuvant analgesics, and other medications.
Non-Opioids. Aspirin, non-steroidal anti-inflammatory drugs (NSAIDS) and
acetaminophen are commonly used non-opioid pain relievers. These medications can be
purchased over the counter or prescribed in higher doses. Some prescription medications
combine non-opioid pain relievers with opioids to treat pain. Aspirin and NSAIDS are
indicated for inflammatory pain whereas acetaminophen does not treat inflammation
(ACPA, 2014).
Opioids. Opioids are used as both fast-acting and long-term treatment of chronic
pain. Opioids are morphine-like substances used to relieve pain (ACPA, 2014). Opioid
use can be a controversial topic in pain management because of the adverse side effects
and potential for opioid abuse and dependence. Common adverse side effects of opioids
include nausea, constipation, thought and memory impairment, and drowsiness (ACPA,
2014). These side effects associated with opioid use often diminish over time or can be
offset with other medications. For example, constipation due to opioid use can be
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managed by using a stimulant laxative plus a stool softener. “It is well known that
prolonged use of opioids may result in problems including hyperalgesia (increased pain
sensitivity), hormonal effects (decreased testosterone levels, decreased libido and sex
drive, irregular menses, etc.), depression, impaired sleep patterns, and suppression of the
immune system (ACPA, 2014).” According to the American Chronic Pain Association
(2014), 51% of all patients taking oral opioids experience at least one adverse side effect.
Because of the side effects, approximately 20% of patients discontinue their use of
opioids. Long-term use of opioid pain relievers may interfere with the body’s natural
pain relievers. Opioid pain relievers such as morphine, hydromorphone, and oxycodone
are available only through prescription from a physician or nurse practitioner. Chronic
pain patients taking prescription opioids may also develop a tolerance over time requiring
a higher dosage to feel relief.
It is best for opioid use to be monitored by a pain specialist who is familiar with
the risks and benefits of using opioids for pain management (ACPA, 2014). Pain
management centers often use an Opioid Treatment Agreement with patients. This
contract can describe patient responsibility in opioid use, specifically by agreeing to only
obtain prescription opioids from one medical provider and to take them as recommended.
Pain management centers also use Urine Drug Screening (UDS) to monitor opioid use in
patients. For example, if a patient is prescribed a daily dose of 100 mg of oxycodone,
then his or her urine should match the amount prescribed. Some patients buy and sell
prescription opioids, which is a major violation of the treatment contract. Prescribers
should discuss safe storage and disposal of opioid medication to help prevent theft, abuse,
and accidental overdose.
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Antidepressants. Antidepressants are also frequently used in pain management to
treat chronic pain and depression. “By increasing levels of chemicals (norepinephrine
and serotonin) at nerve endings, antidepressants appear to strengthen the system that
inhibits pain transmission (ACPA, p. 67).” Antidepressants may be useful in reducing
anxiety and depressed feelings, and help reduce the perception of pain. Antidepressants
can also improve sleep, which is a common problem in pain management. Unlike opioid
pain relievers, antidepressants do not seem to interfere with the body’s internal pain
fighting mechanisms (ACPA, 2014). Pain states that may respond to antidepressants
include postherpetic neuralgia, diabetic neuropathy, phantom limb pain, stump/neuroma
pain, central pain (following stroke), sympathetic dystrophy (CRPS/RSD), chronic
musculoskeletal pain, migraine and tension headache, peripheral neuropathy,
fibromyalgia, irritable bowel syndrome, rheumatoid arthritis, neuropathic pain, and low
back pain with radiculopathy (ACPA, 2014). The three main classes of antidepressant
medications used in pain management are tricycle antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs), and selective serotonin and norepinephrine
reuptake inhibitors (SNRIs).
Anticonvulsants. Anticonvulsant (antiepileptic) drugs are used to treat a variety
or neuropathic pain conditions (ACPA, 2014). Originally developed for the prevention of
epileptic seizures and convulsions, anticonvulsant drugs can be used “off label” to treat
pain. Some anticonvulsants such as pregabalin (Lyrica) and gabapentin (Neurontin) have
been approved by the FDA for treating certain pain disorders like fibromyalgia.
Muscle Relaxants. Muscle relaxants like cyclobenzaprine (Flexeril) and baclofen
(Lioresal) can help calm irritated muscle tissue. Muscle relaxants have limited efficacy
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in chronic pain but may be effective in treating flare-up pain (ACPA, 2014). Muscle
relaxants can have a sedation effect and should be used in caution with opioids.
Topical Pain Relievers. Not all pain relievers are taken orally. Topical pain
relievers or topical analgesics are used to treat neuropathic pain conditions such as
diabetic neuropathy, postherpetic neuralgia (PHN), neuroma pain, and some symptoms of
complex regional pain syndrome (CRPS) (ACPA, 2014). Topical pain relievers are
applied directly to the pain site. Some topical agents contain salicylates that reduce
inflammation and pain. Topical counterirritants (e.g., BenGay, Icy Hot) help relieve
muscle and joint pain by stimulating the nerve endings in the skin and produce a heat or
cooling effect. Many topical pain relievers are available to purchase over the counter.

Behavioral Treatments for Chronic Pain
Behavioral treatments for chronic pain include a variety of interventions and are
designed to shift psychological processes that contribute to pain and distress. As
discussed above, there are several psychosocial factors that influence one’s experience of
pain. Psychological treatment providers can help patients develop stronger self-efficacy,
pain coping strategies, and acceptance in order to improve adjustment to chronic pain
(Keefe et al, 2004). Pain catastrophizing, pain related anxiety and fear, and helplessness
are factors that can be addressed through behavioral treatment approaches. The most
common psychotherapeutic approaches used in pain management include cognitivebehavioral therapy, acceptance and commitment therapy, and operant-behavioral therapy.
Cognitive-behavioral therapy is the leading approach in pain psychology. Adults with
chronic pain can discuss psychosocial factors through individual, couples, family, and
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group counseling. Specific interventions include biofeedback, mindfulness, meditation,
guided imagery, and psychoeducation.
Cognitive Behavioral Therapy for Chronic Pain
Cognitive Elements. Cognitive elements include restructuring negative or
unrealistic beliefs and expectations about pain and developing coping statements (Field,
2008). Patients with chronic pain may form negative beliefs about their pain experience.
In pain management, CBT interventions can be used to identify a patient’s dysfunctional
pain-related thoughts, beliefs, and expectations. After these dysfunctional core beliefs
(schemas) are identified, they can be challenged and replaced with more practical painrelated beliefs. Cognitive therapy targets the negative thoughts and beliefs associated
with pain. Beverly Thorn’s Cognitive Therapy for Chronic Pain: A step-by-step guide
(2004) is an excellent resource for pain management providers. This guide includes
cognitive therapy literature about theory, research, and assessment. It also offers a
manualized cognitive treatment program for treating patients with chronic pain.
Behavioral Elements. Fordyce’s (1974) pain management behavioral program
uses the core concepts of operant conditioning. His program focuses on behavioral
change and reinforcement. Operant conditioning maintains that reinforced behaviors will
increase while punished (or not reinforced) behaviors will decrease. Pain behaviors are
influenced not only by changes in pain intensity, but they also respond to reinforcement.
Fordyce (1974) suggested that pain behaviors could be changed by modifying
reinforcement contingencies of the environment. External systems can reward and
reinforce positive pain-coping behaviors. Positive responses from family, friends,
treatment providers, as well as incentives for treatment adherence can act as reinforcing
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agents for the patient to engage in pain-coping strategies. For example, significant others
can give the patient special attention when he or she engages in behaviors that promote
wellness, which increases the likelihood of the patient continuing this behavior. Using
the same conditioning principles, significant others should not give attention to negative
pain behaviors. If a patient is quick to complain and easily gives up on a stressful task
and his or her significant other is just as quick to accommodate and finish the task, then
complaining and quitting will continue. There is no incentive for the patient to work
through the stressful situation using individual coping strategies. In fact, the significant
other’s accommodations are reinforcing the patient’s helplessness.
In Fordyce’s behavioral treatment program, the external environment is modified
to reinforce (or extinguish) targeted behaviors. Time spent engaging in activities like
household chores and exercise should be reinforced to increase the likelihood of
maintaining these activities. Pain management behavior programs use structure and
schedule as reinforcement. Physical therapy treatment ends once the patient reaches the
targeted number of repetitions, versus stopping when pain increases. Pain medication is
taken on a schedule, versus as needed. The focus is on treatment success instead of
treatment tolerance. Treatment programs using an operant conditioning model focus on
increasing well behaviors through positive reinforcement, shaping and gradual change,
and using extinction to reduce pain behaviors. Pain behaviors involve verbal
communications (e.g., complaints, moaning), motor behaviors (e.g., limping, guarding),
activity level (e.g., time spent sitting or lying down), and use of medical and
pharmacological interventions (e.g., emergency department visits, opioid use).
Behavioral treatment focuses on modifying reinforcers in the environment in attempts to
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increase behavioral activation. Behaviors are changed through shaping and gradually
increasing activity, goal-setting, and pacing. Behaviors such as effective communication
skills, sleep hygiene, and proper diet can also be reinforced by external systems.
Components of Cognitive-Behavioral Therapy. There are several core
components of cognitive-behavioral programs used in the treatment of chronic pain:
education, goal-setting, skill acquisition, cognitive, maintenance, and exercise (Field,
2008). Patient education can help one’s understanding of pain and its effects. Increasing
knowledge about the biological, psychological, and social factors that impact pain can
influence a patient’s behavior. A patient might be more willing to make a quit attempt
with nicotine if he or she learns about how smoking cigarettes can alter the effectiveness
of pain medication. Goal-setting with a cognitive-behavioral approach can apply to both
short-term and long-term goals. Patients can set individual goals as well as treatment
goals. Relaxation techniques are often presented as part of cognitive-behavioral
programs in pain management. Guided imagery, meditation, and mindfulness practices
can be used as self-management strategies for pain. Body relaxation can influence pain
in several ways: to help manage stress levels, reduce muscle tension, distract from pain,
and help with sleep, both falling asleep and staying asleep. Pain management programs
using a CBT approach can also focus on patient skills. Acquiring self-care skills can
improve treatment adherence. Learning how to talk about pain can improve their
communication skills with caregivers and providers. Activity pacing and stress
management skills can influence one’s level of pain. Good sleep hygiene is invaluable
for anyone, especially those with chronic pain.
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Pain affects and is affected by cognitions. It is helpful for a patient to identify
pain-related cognitions, beliefs, fears, and expectations. If a patient has the expectation
that he or she should experience 100% pain relief after a treatment, then that patient will
more than likely be disappointed. However, if the patient adjusts his or her expectations
to moving two numbers down on a numeric (0 to 10) pain rating scale, then the treatment
may be viewed as more of a success. CBT programs can also help someone develop
pain-coping statements. As the patient starts to understand his or her pain experience,
patterns can be identified. The patient may be able to anticipate problems more easily
and develop strategies for coping with setbacks.
Cognitive-behavioral interventions can be provided alone or as one part of a
larger treatment plan that includes other treatments such as physical therapy and medical
therapies. The cognitive-behavioral approach can be adapted for individual or group
therapy. Individual therapy offers the opportunity for the patient to get the treatment
provider’s undivided attention and intervention programs can be tailored to meet the
needs of the patient. Advantages of group therapy include social interaction, peer
support, sharing of ideas, modeling of adaptive behaviors, and opportunities for group
members to validate their experience of pain,
Some CBT programs ask patients to complete homework assignments between
sessions. Homework assignments can help the patient integrate therapeutic material into
everyday activities. Keeping a pain diary as homework can be helpful in identifying
variables (the weather, activities, strong emotion, stress levels, etc.) that can influence
daily fluctuations in pain. Patients can also journal their responses to changes in pain
such as taking medication, resting, applying heat or ice, stretching, or using relaxation
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techniques. This can highlight which pain coping strategies the patient is using most
frequently and may identify the need to develop a broader range of techniques.
Goal Setting. Patients and providers can set goals in order to increase activity. A
treatment plan should include long-term and short-term goals. Short-term goals can act
as attainable steps toward long-term goals. Pain management providers can help patients
identify goals and expected time frames. These goals can be modified based on the
patient’s response and perception of difficulty. Goals should be realistic and achievable
for the patient. For a patient who has had several back surgeries and continues to have
low back pain, getting a physically demanding job that involves a lot of bending and
lifting may not be realistic. Steps toward job retraining and vocational rehabilitation may
be more manageable for the patient. Short-term goals can include making contact,
getting information, completing training classes, making a resume, and applying for jobs
with the long-term goal of part-time non-labor employment. There should be some
desirability for the goal to be accomplished. Giving a patient a list of things he or she
should be doing does not take into account the feelings of the patient. Goals should be
patient-centered. Success is more likely when patients want to attain a specific goal.
Group treatment can act as behavior reinforcement. Positive feedback from other
group members can positively reinforce goal-directed behaviors (Field, 2008). The group
can help a patient acknowledge the importance of seeing small steps as successful
accomplishments. Patients can have difficulty acknowledging accomplishments when
they compare their present abilities to what they might have been capable of in the past.
A lot of patients can no longer do what they once did and may view this as failure.
Effectiveness Research of Cognitive-Behavioral Therapy for Chronic Pain
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Cognitive-behavioral approaches in pain management typically involve
psychoeducation, skills-building using relaxation training, activity pacing, distraction
strategies, cognitive restructuring, problem-solving, and goal development. Patients are
encouraged to apply their skills in times of distress (Warfield & Fausett, 2002). The goal
is to increase one’s level of functioning and resiliency. The Cochrane Library (2013)
published a systematic review to evaluate the effectiveness of psychological therapies for
chronic pain. Their review included 35 randomized controlled trials with data on 4788
participants. When compared to active controls, they found that CBT has a small positive
effect on disability and pain catastrophizing but not on pain or mood. Immediately after
treatment, CBT had small to moderate effects on pain, disability, mood, and
catastrophizing but these effects faded at the 6-month follow-up. One of the main
conclusions of the Cochrane Review (2013) is that there are insufficient data on the
quality and content of psychological treatments for pain management, which makes it
difficult to systematically analyze outcomes.
The use of CBT has been studied with patients who have arthritic knee pain
(Keefe et al., 1990a,b) and RA pain (Parker et al., 1988). As a result of this research,
CBT was found to be an empirically supported therapy by the APA Division 12 Task
Force (APA, 2006). Morley and colleagues (1999) did a meta-analysis that determined
cognitive-behavioral interventions to be more effective in the treatment of various pain
conditions when compared to active controls. They found that the CBT group
experienced changes in the domains of pain experience, mood/affect, reducing negative
coping, and increasing negative coping. In comparison to wait list controls, CBT was
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shown to be a more effective treatment in the domains of pain experience, positive
coping, and social role function.
Research on the efficacy of CBT in pain management has its obstacles. First, how
treatment outcomes are defined differs from study to study. A successful treatment
outcome can be defined as “pain reduction, pain interference (the extent to which pain
interferes with daily activity), improved mood, fewer pain behaviors, decreased use of
pain medications, return to work, and decreased health care utilization (Field, p. 81).”
Secondly, it is hard to isolate mental health intervention as a single variable when
patients are taking prescription pain medications and participating in medical treatments
or physical therapy. Finally, there is a lack of standardization across CBT programs used
in the treatment of chronic pain.

Treatment for Chronic Migraine
Treatment for chronic migraines should focus on prophylactic, or preventative,
therapy (Garza & Schwedt, 2015). Prophylactic interventions include pharmacotherapy,
behavioral therapy, physical therapy, and other treatments aimed at prevention. Use of
acute medications should be minimal. Also, patients should maintain a regular schedule
and try to avoid migraine triggers. The most frequently reported triggers are stress
(79.7%), not eating (57.3%), weather (53.2%), sleep disturbance (49.8%), perfume or
odor (43.7%), neck pain (38.4%), light(s) (38.1%), alcohol (37.8%), smoke (35.7%),
sleeping late (32.0%), heat (30.3%), food (26.9%), exercise (22.1%), and sexual activity
(5.2%) (Kelman, 2007). Headache diaries can be helpful in tracking things like triggers,
sleep, exercise, and medication use. Lifestyle regulation is an important part of a
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comprehensive headache treatment plan. Long-term management for chronic migraines
usually involves using different therapeutic modalities (e.g., pharmacotherapy, physical
therapy, acupuncture, relaxation training) simultaneously to reduce the frequency and
intensity of migraine headaches.
Principles of Migraine Headache Treatment
The American Academy of Neurology (AAN) Quality Standards Subcommittee
published a report on practice parameters and evidence-based guidelines for the treatment
of migraine headache based on the current research literature (Silberstein, 2000). This
report identified five general principles of headache management. The first principle is
for the treatment team to establish an accurate diagnosis. The International Classification
of Headache Disorders, 3rd edition identifies the diagnostic criteria for different types of
headaches. The International Classification of Diseases (ICD-10b) uses the International
Headache Society headache classification system (ICHD-3). The second principle for
migraine headache treatment is to “Educate migraine sufferers about their condition and
its treatment. Discuss the rationale for a particular treatment, how to use it, and what
adverse events are likely” (Silberstein, 2000, p.3). It is helpful for patients to understand
their condition and have access to quality information. Clinicians should discuss
potential benefits and risks of specific treatments in order for patients to make informed
decisions about their care.
The third principle of headache management is to “Establish realistic patient
expectations by setting appropriate goals and discussing the expected benefits of therapy
and how long it will take to achieve them. Empower the patients to be actively involved
in their own management by encouraging patients to track their own progress through the
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use of diary cards, flow charts, headache calendars, and forms of tracking days of
disability or missed work, school, or family activities. Treatment choice depends on the
frequency and severity of attacks, the presence and degree of temporary disability, and
associated symptoms such as nausea and vomiting.” (Silberstein, 2000, p.3). Patients
should have realistic expectations of treatment benefits and timelines. A patient who
expects to experience 100% relief after one treatment is going to be disappointed when he
or she experiences 30% or 50% relief. The patient may consider the treatment to be
unsuccessful, even if 50% relief is considered to be a good outcome by the treatment
team. Patients should be encouraged to track specific headache factors (e.g., intensity,
duration, triggers, medication use, etc.) through use of a headache diary or other forms of
tracking. It is helpful for patients and their treatment team to identify patterns and patient
progress over time when making decisions about treatment directions.
The fourth treatment principle identified by the AAN Quality Standards
Subcommittee is to “Create a formal management plan and individualize management:
consider the patient’s response to, and tolerance for, specific medications. Consider
comorbidity/coexisting conditions. Coexisting conditions (such as heart disease,
pregnancy, and uncontrolled hypertension) need to be ascertained as they may limit
treatment choices.” (Silberstein, 2000, p.3). Headache treatment plans should be
individualized based on the patient’s unique circumstances. Each patient is different and
responses to medications vary. Other medication options should be discussed if a patient
cannot tolerate the side effects of one specific medication. Patients should be treated as a
whole person. A neurologist should not ignore other co-existing medical conditions,
especially conditions that may affect headache treatment. This is especially important
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when prescribing medication so the patient is not prescribed drugs that interact adversely
when taken together. The final principle of headache management is to “Encourage the
patient to identify and avoid triggers.” (Silberstein, 2000, p.3). Headache diaries can be
helpful in identifying and tracking headache triggers. Once a patient is able to identify
specific headache triggers, he or she can try to avoid or minimize these triggers when
possible.
Acute Migraine Treatment Goals
The AAN also identified goals of acute migraine treatment in their evidencebased review of research literature. The first goal is to treat migraines “rapidly and
consistently without recurrence” (Silberstein, 2000, p.3). For optimal headache relief,
migraine attacks should be treated immediately. The second goal of acute migraine
treatment is to help the patient return to his or her usual functioning ability. Minimal use
of back-up or rescue medications is the third goal of acute migraine treatment. Rescue
medication is used when other regular treatments fail. Patients can use rescue medication
at home and avoid a visit to the physician’s office or emergency department. The fourth
goal of the AAN treatment guidelines is to empower patient self-care and reduce
unnecessary use of rescue medications. Patients are encouraged to try deep breathing or
relaxation exercises before taking potent rescue medications. Another identified goal of
acute migraine treatment is to try to be as cost-effective as possible. Unnecessary use of
medical resources, such as treatments, tests/scans, and no show appointments, is a waste
of time, energy, and money. The final goal discussed in the practice parameters is to
have as few adverse events (e.g., medication over-use headache) as possible.
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Overall, the objective of acute treatment is to help the patient return to “normal”
using as few treatments as possible with the patient acting as an active participant in
treatment. Success of acute treatment is defined by the frequency with which an
individual can return to a headache-free, fully functional state within 2 hours of an attack
(Silberstein, 2000). Another measure of treatment success is whether or not there was
recurrence of headache within 24 hours of the attack treated (Silberstein, 2000).
Preventative Treatment for Migraine
Many migraineurs can benefit from preventative, or prophylactic, treatment.
There are not specifically identified criteria (e.g., frequency, duration, etc.) to prompt the
initiation of preventative treatment for migraine, though more than 4 headaches per
month or headaches that last for more than 12 hours are generally accepted as reasonable
thresholds (Bajwa & Smith, 2015). Preventative treatment is also indicated when
migraine attacks cause significant distress, diminished quality of life, or significant
impairment/disability despite regular acute treatment. When acute therapies fail or cause
serious adverse effects or contraindications, prophylactic treatments should be
considered. Some patients request preventative measures for self-care. Medication is a
major component of preventative care. Therapeutic lifestyle choices can also have a
major effect on the course of headache. Routine meals, regular exercise, good sleep
hygiene, and avoidance of migraine triggers can be part of a comprehensive preventative
treatment plan. Goals of migraine preventative therapy are “1) reduce attack frequency,
severity and duration; 2) improve responsiveness to treatment of acute attacks; 3)
improve function and reduce disability.” (Silberstein, 2000, p. 7).
Long-Term Migraine Treatment
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Goals of long-term migraine treatment, both pharmacologic and
nonpharmacologic, were also identified in the AAN’s evidence-based review (Silberstein,
2000). The first and primary goal of treatment is to reduce headache attack frequency
and severity as well as disability related to headache. Intensity and type of care are based
on the patient’s level of disability and symptomatology. The focus of acute treatment is
to decrease the symptoms associated with an ongoing headache attack. The second goal
of long-term treatment is to “reduce reliance on poorly tolerated, ineffective, or unwanted
acute pharmacotherapies.” (Silberstein, 2000, p. 2). If a medication is ineffective or
poorly tolerated, then it is not appropriate to continue use. The treatment team may make
the decision with the patients to discontinue a medication with many adverse side effects
that only provides minimal relief. Another goal is to improve the patient’s overall quality
of life. Pain can affect more than a patient’s physical health; it can affect mental health,
relationships, participation in work, school, or social activities, ability to carry out
activities of daily living, and other aspects of an individual’s life. A patient may report
similar pain levels over time, but his or her reported depression has decreased and
therefore the patient is able, for example, to attend more family social events. Quality of
life can change even if reported levels of pain remain the same. The fourth goal is to
avoid continuing increased use of acute medication. The AAN guidelines state to
“Consider preventative treatment (given on an ongoing basis whether or not an attack is
present) for those patients whose migraine has a substantial impact on their lives and
have not responded to acute care, or where frequency of migraine attacks is such that the
reliance on the acute care medications would increase the potential for drug-induced
(rebound) headache.” (Silberstein, 2000, p.2). Another goal is to help educate and
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encourage patients to enhance personal control and management of their headache
condition. Patients should be active participants in tracking patterns and progress over
the course of treatment. The final goal of long-term migraine treatment is to decrease
headache-related psychological distress. A comprehensive headache treatment plan
includes a biopsychosocial approach.
Pharmacological Treatment for Migraine Headache
When choosing pharmacological treatment for migraine, individual patient factors
are a big influence. The presence of comorbid medical and psychological disorders
should always be assessed. Sleep difficulties, chronic fatigue, and gastrointestinal
complaints should be considered when prescribing medications. Specific principles of
prophylactic therapy can be applied to increase the chances of success and minimize
complications regardless of the type of medication chosen. These principles include: 1.
Start oral drugs at a low dose and increase gradually, 2. Give the chosen medication an
adequate trial, 3. Avoid overuse of acute headache medications, 4. Avoid valproate for
women of childbearing potential, 5. Address patient expectations and preferences (Garza
& Schwedt, 2015).
First-Line Agents. Prophylactic medications used for episodic migraine also can
be used in the prevention of chronic migraine. First-line prophylactic medications
include propranolol, amitriptyline, topiramate, valproic acid and its derivative (for men).
These are medications to try first. “It is expected that up to 50% of patients treated with
one of these medications will have at least a 50% reduction in the frequency of headaches
after three months of treatment, given adequate doses” (Garza & Schwedt, 2015). Side
effects are frequently reported with these prophylactic agents which limits their use.
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Second- and Third-Line Agents. If adequate trials of first-line agents are
ineffective or poorly tolerated, there are other alternatives. Second-line agents include
botulinum toxin type A (onabotulinumtoxinA), valproic acid and its derivatives (secondline for women due to teratogenicity), butterbur, verapramil, other beta blockers
(atenolol, nadolol, metoprolol, timolol), gabapentin, magnesium, riboflavin, candesartan,
and other tricyclic antidepressants (nortiriptyline, protriptyline). Third-line agents used
in prophylactic treatment for migraine include feverfew, tizanidine, memantine,
pregabalin, cyproheptadine, and zonisamide.

Behavioral Treatments for Migraine Headache
Behavioral interventions can serve as a crucial part of a larger comprehensive
treatment plan. Headache treatment teams should consider behavioral therapies when
there is poor tolerance or an inadequate response to medication or when pharmacological
treatment is contraindicated. Some patients are against taking medication and request
other types of interventions. Behavioral treatments can be helpful with life stress,
inadequate coping skills, or comorbid mental health issues that may aggravate headache
symptoms and patient disability. Behavioral treatments are classified into three broad
categories: cognitive-behavioral/stress-management training, relaxation training, and
biofeedback (Silberstein, 2000). These three categories of behavioral therapies will be
discussed separately.
Cognitive-Behavioral Therapy/Stress-Management Training
The way an individual copes with stress can precipitate or exacerbate headache
symptoms and increase headache-related disability. CBT can help patients become more
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aware of how cognitions influence stress responses. “Patients are then assisted in
identifying the specific psychological or behavioral factors that trigger or aggravate their
headaches, and then taught to employ more effective strategies for coping with headacherelated stress. By assisting patients to more effectively manage stress, CBT can help to
limit the disability, anxiety, and depression that often afflict patients with more frequent
and severe headaches.” (Penzien et al., 2005, pg. S113). Cognitions about stress, pain, or
disability are targeted. Catastrophizing is a common thought pattern among patients with
pain. Thoughts like “I’m unable to tolerate pain and must have immediate relief” can
have a negative effect on a patient’s ability to function. A goal of CBT is to help patients
identify and challenge their unhealthy pain cognitions, as well as manage headacherelated stress and enhance healthy coping mechanisms. Cognitive behavioral therapy
should be done by a trained mental health provider.
Relaxation Training
Because life in modern society tends to be stressful and fast-paced, relaxation
training can be helpful to most people. Three types of relaxation training are commonly
used in treatment for chronic headaches: progressive muscle relaxation, autogenic
training, and meditation or passive relaxation (Penzien et al., 2005). With progressive
muscle relaxation, patients are asked to tense and relax specific muscle groups
throughout the body. Autogenic training involves the patient using warmth and
heaviness to promote a state of deep relaxation. Meditation or passive relaxation
involves deep breathing and repeating words or sounds to calm the mind and body. The
skills taught in relaxation training are used more often as preventative therapy rather than
abortive therapy. A major goal of relaxation training is to enable patients to gain a better
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sense of control over their physiological responses and sympathetic arousal (Penzien et
al., 2005). Relaxation training may consist of 10 or more sessions for patients with
complicated headache symptoms. Patients can practice relaxation skills at home.
Biofeedback Training
Thermal and Electromyographic Biofeedback. The two types of biofeedback
most commonly used in treating chronic headaches are thermal feedback and
electromyographic (EMG) biofeedback (Penzien et al., 2005). Thermal feedback, or
handwarming, measures finger temperature. EMG biofeedback monitors the electrical
activity from muscles of the scalp, neck, and upper body. Biofeedback teaches the
patient to control bodily functions that are normally involuntary and done unconsciously
(i.e., breathing, heart-rate) (Penzien et al., 2005). One can observe his or her body’s
reaction to stress and then develop the ability to recognize and reduce tension in the body.
The biofeedback instrument measures the body’s response and then a patient can try to
alter or calm his or her physiological state. Biofeedback training can be combined with
relaxation training. This allows the patient to get feedback on their relaxation and selfregulation skills. Patients can practice their relaxation skills using the biofeedback
equipment and then use them in stressful situations in real-life. Biofeedback training is
often referred to as “mind over migraine,” and research shows it can reduce migraine
pain and frequency (Blanchard & Andrasik, 1987; Blanchard et al., 1980; Nestoriuc et al.,
2008a; Nestoriuc, 2008b).
Heart Rate Variability. Some biofeedback programs measure heart rate
variability to assess internal arousal activation. The heart rate variability is derived from
intervals between normal heart beats (NNs) (Goldberger & Stein, 2013). The change in
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time intervals between adjacent heart beats indicates the body’s response to stress,
emotional arousal, and activation of the autonomic nervous system. HRV biofeedback is
designed to target autonomic reactivity within the body: “Training involves slowing the
breathing rate to the frequency at which, in each individual, amplitude of HRV is
maximized” (Hassett et al., 2007, p. 3).

Biofeedback Training
Biofeedback Training with Headache
The effectiveness of biofeedback has been studied and examined for decades.
Early reviews of biofeedback treatment with chronic headaches (migraines and tension
type headaches) reported 40% to 65% improvement (Blanchard & Andrasik, 1987;
Blanchard et al., 1980). More recently, two meta-analyses (Nestoriuc et al., 2008a;
Nestoriuc et al., 2008b) reviewed the research literature on the use of biofeedback
training with migraine and tension-type headache and found sound evidence supporting
its effectiveness. The meta-analysis by Nestoriuc and colleagues (2008) found a medium
to large overall effect size (N=788, d=0.73; 95% CI=0.61, 0.84). “The significant
medium-to-large effect size from pre-to post-treatment was replicated in comparison to
untreated CGs. A significant medium effect size favoring biofeedback was found in
comparison with that of placebo CGs and a significant small effect size for biofeedback
in comparison with that or relaxation CGs.” (Nestouric et al., 2008).
The Quality Standards Committee of the American Academy of Neurology
generated evidence-based guidelines for treating migraine headaches based on the current
research literature (Silberstein, 2000). Biofeedback and relaxation training were listed
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under cognitive and behavioral treatment recommendations. “Relaxation training,
thermal biofeedback combined with relaxation training, electromyographic biofeedback,
and cognitive-behavioral therapy may be considered as treatment options for prevention
of migraine (Grade A)” (Silberstein, 2000). Grade A therapies are established as
effective treatment options and should be offered to patients for migraine prevention.
Also, the guidelines recommend combining behavioral therapy with preventative drug
therapy for further improvement and migraine relief, which is classified as Grade B.
Grade B therapies can be effective and should be considered as options for migraine
prevention treatment.
Nestouric and colleagues (2008) examined the research literature on biofeedback
with headache (migraine and TTH) and put together a comprehensive efficacy review.
They determined that biofeedback training for migraine can be considered an efficacious
treatment option. According to AAPB/ISNR criteria (LaVaque et al. 2002), the research
on biofeedback for migraine represents Level 4 evidence. Multiple research teams, using
sound research methodology, found biofeedback to be beneficial when compared to notreatment control groups. This efficacy review also concluded that biofeedback for TTH
can be supported as an efficacious and specific treatment option. This constitutes Level 5
evidence, which is the highest level of evidence, according to AAPB/ISNR criteria
(LaVaque et al. 2002). Level 5 interventions have established Level 4 evidence and have
shown additional treatment outcomes (improvement) compared to credible sham therapy
or alternative bona fide treatments (Nestouric et al., 2008).
Biofeedback Training with Chronic Pain
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In Sweden, a pilot study was conducted to examine the effects of HRV
biofeedback with patients who experience stress-related chronic neck pain (Hallman et
al., 2011). The study included 24 participants who were randomly assigned to the
treatment or control group. Recruitment for the study was done through a stress clinic and
recommendations from associated physiotherapists. Also, the research team sent
invitations to public service employees in two cities in the Stockholm area. Inclusion
criteria were based on age (20 to 50 years) and “perceived pain and/or other symptoms of
muscle discomfort primarily located to the neck-shoulder area, observed for at least 6
months and persistently over the last 6 consecutive weeks. Diagnosis of neck-shoulder
pain and stress related symptoms were evaluated by a specialized psychologist.”
(Hallman et al., 2011, p. 72). The 12 people assigned to the treatment group engaged in
10 weekly sessions of resonance HRV biofeedback training facilitated by a licensed
psychologist. The control group engaged in breathing exercises identified in the protocol
for Session 1 and 10 of the biofeedback training program. The control group did not
receive any other treatment between Session 1 and 10. Both groups completed an
extensive assessment battery the week before and after the intervention.
In this pilot study, the Hospital Anxiety and Depression Scale (HAD) was used to
measure levels of anxiety and depression. The two subscales (anxiety and depression)
have scores that range from 0 to 21. Scores above 10 suggest clinical levels of anxiety or
depression. After 10-weeks, participant reports of perceived anxiety and depression
decreased in both the treatment and the control group, however the overall effect of
treatment was not found to be significant when the two groups were compared.
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Health-related quality of life and functioning was measured using the Short Form
36 Item Health Survey (SF-36). This 36-item assessment has 8 different subscales (i.e.,
physical function, physical role, bodily pain, general health, vitality, social function,
emotional role, and mental health) addressing factors of mental and physical health.
Subscale scores range from 0 to 100 with higher scores indicating better perceived health.
The pre-treatment SF-36 scores were similar between the treatment and control groups.
Post-treatment scores showed significant interaction effects (group x time) for several
subscales including vitality (p=.005), social function (p=.047), and bodily pain (p=.049)
with higher ratings over time for the treatment group compared to controls. Both the
treatment and the control group had increased scores of physical function, bodily pain,
and vitality over time (p<.05). These results indicate that participants reported
improvement in perceived health and functioning over a 10-week HRV biofeedback
training program.
The use of HRV biofeedback was also studied with patients diagnosed with
fibromyalgia (Hassett et al., 2007). This pilot study included 12 female participants
between the ages of 18 and 60, who had a physician-confirmed diagnosis of fibromyalgia
using diagnostic criteria established by the American College of Rheumatology (Wolfe et
al., 1990). All 12 patients participated in 10 weekly biofeedback sessions. In addition,
participants were instructed to practice strategies at home twice a day for 20 minutes.
The Beck Depression Inventory-II (BDI-II) was used to measure cognitive,
affective, and neurovegetative symptoms associated with depression. In order to make
the BDI-II more appropriate for use with a chronic pain population, less sensitive to
medical factors, items addressing weight loss, changes in body image, and somatic
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preoccupation were replaced. These modifications make the instrument less sensitive to
medical factors and more consistent with DSM criteria for depression. Pre-treatment
scores showed 8 out of the 12 participants met criteria for at least mild depression, with 3
of these participants in the severe range. Between Sessions 1 and 10, there were
significant decreases on the total BDI-II scores (unadjusted p=.0089, adjusted p=.044).
These results continued at the 3-month follow-up (unadjusted p=.0055, adjusted p=.036).
This study gives evidence of the effectiveness of HRV biofeedback in treating
psychosocial symptoms associated with fibromyalgia.
In this study, the Fibromyalgia Impact Questionnaire (FIQ) was used to assess
physical impairment, physical functioning, pain, fatigue, sleep quality, muscle stiffness,
anxiety, and depression (Burckhardt, Clark, & Bennett, 1991). The overall score of this
19-item self-report questionnaire was used to measure participant functioning. At
Session 1, the baseline mean score on the FIQ in this sample (M=55.5, SD=18.4) was
slightly above the expected mean (M=50.0). Improvements in functioning based FIQ
scores from Session 1 to Session 10 were not significant. However, significant
improvements in functioning were seen from Session 1 to the 3-month follow-up session
(unadjusted p=.002, adjusted p=.018). Although the effects of the biofeedback training
were not significant immediately after the intervention, significant improvements in
patient functioning were seen 3 months after the intervention. This may be because the
participants were able to continue practicing exercises learned through biofeedback
training and found more improvement as they mastered the techniques.
Objectives for Biofeedback with Chronic Pain
The two main objectives for biofeedback training are to help “increase awareness
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of often subtle mind-body connections, and to promote learning of psychophysiological
self-regulatory strategies. Such learning can result in reduced reactivity to critical
stimuli, accelerated recovery from a stress response, and enhancement of perceived selfefficacy and coping skills mastery” (Warfield & Fausett, 2002, p. 334). Reducing pain is
a secondary goal. Some patients are successful with a biofeedback training program but
report little to no pain relief. However, treatment effectiveness cannot be judged by pain
ratings alone. Treatment progress in biofeedback training should be measured by several
factors from a biopsychosocial approach.
The purpose of relaxation techniques and biofeedback training is to help patients
with chronic pain become more aware of the body’s physiological processes that are
normally done automatically. Once they become more aware of changes in the body
(e.g., muscle tension, heart rate, skin temperature, respiration, etc.), they can exert some
control and initiate a different response. For example, through biofeedback training a
patient can observe his or her heart rate increase or changes in breathing patterns and
even link these changes to specific cognitions. This feedback can be particularly helpful
with patients who experience muscle tension/fatigue associated with pain.

Discussion
The research literature on the effectiveness of biofeedback training for headache
is encouraging. Biofeedback training is considered a highly effective treatment for
migraine and tension-type headache (Blanchard and Andrasik, 1987; Blanchard et al.,
1980; Nestoriuc et al., 2008a; Nestoriuc et al., 2008b). The efficacy evidence for
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biofeedback has been strong for decades. Early reviews found reports of 40% to 65%
improvement (Blanchard and Andrasik, 1987; Blanchard et al., 1980). Two more recent
meta-analyses reviewed the research on biofeedback training with headache and found a
medium to large effect size overall (Nestoriuc and Martin, 2007; Nestoriuc et al., 2008).
The American Academy of Neurology classifies biofeedback as Grade A treatment for
migraine, which means it is a highly effective treatment for migraine and should be
considered when discussing treatment options. Biofeedback training was also classified
as Grade B and the AAN guidelines recommended combining biofeedback with other
types of therapies for further improvement and relief (Silberstein, 2000).
Biofeedback training is also used to treat other types of pain and pain conditions.
The American Chronic Pain Association lists biofeedback as a mind-body intervention
for pain. However, there is little research evidence to support the effectiveness of
biofeedback training with chronic pain, especially HRV biofeedback. Two pilot studies
examined the effects of HRV biofeedback with chronic neck pain (Hallman, et al., 2011)
and fibromyalgia (Hassett, et al., 2007) and found improvement in health and functioning
as well as significant decreases in depression and pain. These results are encouraging but
there is more to learn about treatment outcomes associated with HRV biofeedback and
chronic pain.
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Chapter 3: Methods
This was an archival study based on a retrospective cohort design. Data
collection was done in the form of patient chart and records review. It is standard
practice in the pain management center where the data were collected to regularly gather
patient report of various types of health and wellness information, as well as patient
report of several factors related to pain, to help track patient progress over time. This
study used patient report and health information to assess the effectiveness of the
biofeedback training program as a behavioral intervention for chronic pain in addition to
examining a variety of variables that may moderate the effectiveness of the intervention.

Participants
Information from patients who participated in a mindfulness-based heart rate
variability biofeedback program at a pain management center in the Midwestern U.S. was
used in this archival study. These patients were referred to the biofeedback program by a
member of the pain management team or by other specialists within the associated
hospital system (e.g. Neurology, Physical Medicine & Rehabilitation). Upon receiving a
referral, the lead psychologist at the pain management center evaluates the patient and
makes a determination of whether or not the patient is an appropriate candidate for the
mindfulness-based heart rate variability biofeedback training program. Exclusionary
criteria for biofeedback include being actively psychotic or having a compromised mental
status. Patients with severe suicidal ideation may require a higher level of mental health
treatment before participating in the biofeedback training. Some patients who have
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substantial medical and/or psychiatric comorbidities that are deemed likely to interfere
with their ability to fully participate are also not referred to the biofeedback training
program.
Another exclusionary criterion in this study involved the use of pain medications
in dosages higher than 100mg of morphine equivalent per day. As a general practice, the
pain management center where the study data were collected does not prescribe pain
medications in daily dosages of 100mg of morphine equivalent or above. The side
effects of such high dosages of pain medication may interfere with a patient’s ability to
fully engage in and benefit from this biofeedback training program. The patients who
participated in the biofeedback program were not using pain medications in dosages
higher than 100mg of morphine equivalent per day. Other types of medications
prescribed to each patient were recorded but they did not act as either exclusionary or
inclusionary factor for this study.
Inclusionary criteria for participating in this study included being between 18 and
80 years old and having a physician-confirmed diagnosis of a chronic pain condition,
which is pain that lasts for more than 3-6 months. Types of pain and pain conditions
included in this study were neuropathic pain, musculoskeletal pain, and headache.
Patients must have completed at least three sessions of biofeedback training with each
session lasting at least 10 minutes. Patients with less than 30 minutes of training are less
likely to experience the potential benefits of the intervention. The biofeedback program
requires the patient to demonstrate the ability to sustain a calm state, which is difficult to
establish in fewer than 10-minute sessions.
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In total, there were 146 patients who participated in the biofeedback training
program from August 1, 2015 to August 1, 2016, during the first year after the
biofeedback program was established at the pain management center. There were 45
patients who had one session and 29 patients who had two sessions. Some of these
patients came for one or two sessions and decided not to continue with the biofeedback
program. Other patients started the biofeedback training and were planning on
continuing the program, but had less than three sessions at the time of data collection so
they did not meet the criteria and were not included in this study.
There were 72 patients total who received three or more sessions of mindfulnessbased biofeedback training at the pain management center between August 1, 2015 and
August 1, 2016. There were 56 females (77.8%) and 15 males (20.8%) as well as one
individual who identifies as transgender (1.4%). The age of the participants ranged from
18 years to 78 years old with a mean of 46.94 (SD = 13.81). Almost two-thirds of the
sample (61.1%) was under the age of 50 years old. Fifty-one participants (70.8%)
identified as white or Caucasian. Sixteen participants (22.2%, n=16) identified as black
or African American and five participants (6.9%) identified as Latino or Hispanic.
Twenty eight participants (38.9%) reported being married with another three
(4.2%) who reported having significant others. About a third (31.9%, n=23) reported
being single. The rest of the patients were either divorced (22.2%, n=16) or legally
separated (2.8%, n=2).
Thirty-one participants (43.1%) reported not having any children. Twelve people
(16.7%) reported having one child, thirteen people (18.1%) had two children, eleven
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people (15.3%) had three children, four people (5.6%) had four children and one
participant (1.4%) reported having twelve children.
More than a quarter of the sample (26.4%, n=19) was employed full-time and
another 12.5% (n=9) employed part-time. A quarter of the sample (25%, n=18) was
receiving social security disability income with another 16.6% (n=12) who were in the
application process for social security disability (e.g. were awaiting a decision, were
denied, appealed and awaiting a hearing). In addition, 9.7% (n=7) reported being
unemployed and another 9.7% (n=7) reported being retired from working.
Fifteen participants (20.8%) reported having a high school diploma or equivalent
and one person (1.4%) had less than a high school education. Approximately 8.3% (n=6)
had attended a technical school or certificate program and 5.6% (n=4) had an associate’s
degree. Another 16.7% (n=12) of the sample reported that they had attended some
college. Almost half of the participants (47.2%, n=34) had a bachelor’s degree or higher
with 31.9% (n=23) holding a bachelor’s, 12.5% (n=9) holding a master’s, and 2.8% (n=2)
holding a doctorate. The level of education in this sample was higher than the national
average. This study sample had 47.2%, (n=34) who had a bachelor’s degree or higher
while the national average of adults in the United States who have a bachelor’s degree or
higher is 33% (U. S. Census Bureau, 2015).
The patients reported that had experienced pain for significant amounts of time.
Two-thirds (n=49) reported experiencing chronic pain for at least a decade and 30
participants (42%) for 20 years or more. None of the patients reported having chronic
pain for less than one year.
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Table 3.1 Duration of Pain
Frequency Valid Percent Cumulative Percent
1-2 years
2
2.8
2.8
2-3 years
2
2.8
5.6
3-4 years
5
6.9
12.5
5-10 years
14
19.4
31.9
11-15 years
10
13.9
45.8
15-20 years
9
12.5
58.3
20+ years
30
41.7
100.0
Total
72
100.0
Measures
Independent Patient Report
It is standard practice to collect patient data at every appointment at the pain
management center. The Independent Patient Report form is given to patients to
complete before each appointment for psychological services. The Independent Patient
Report can be found in Appendix A.
The first section of the Independent Patient Report asks patients to answer
questions about pain location and current level of pain using the numeric rating scale of 0
to 10. Patients are also asked to report their current distress level on a scale of 0 to 10.
Patients are asked to “Circle the word or words that applies best to your pain (circle as
many as apply to you)”. The descriptive terms provided include: throbbing pain,
shooting pain, stabbing pain, sharp pain, cramping pain, gnawing pain, hot-burning pain,
aching pain, heavy pain, tender, splitting pain, tiring-exhausting, sickening, fearful,
punishing-cruel, electric-shock pain, cold-freezing pain, piercing, pain caused by light
touch, itching, tingling or “pins and needles”, and numbness. Patients are asked to rate
how their pain has changed since their last appointment with four choices: Not changed;
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Improved temporarily; Improved; Deteriorated. They are also asked to rate their
percentage of pain relief since their last visit from 0 to 100%. The final question asks, “Is
there anything specific that you want to discuss today? Yes / No Please briefly
describe.” Patient responses to this question were used to help the biofeedback facilitator
choose specific activities for that session.
Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS; Sullivan, Bishop, & Privik, 1995) is a 13item instrument that asks patients to reflect on various pain experiences and indicate how
often they thought about each experience. The PCS uses a 5-point response scale where
0 represents “not at all” and 4 indicates “all the time.” The PCS has three empirically
derived subscales: magnification, rumination, and helplessness. Magnification refers to
an exaggeration of the threat value associated with pain (e.g., “I wonder whether
something serious may happen”). Rumination happens when the patient’s attention is
constantly focused on the pain (e.g., “I can’t seem to keep it out of my mind”).
Helplessness is assessed through a patient’s beliefs about his or her ability to cope with
pain (e.g., “There’s nothing I can do to feel better”). In the original PCS validation study
(Sullivan et al., 1995), the Magnification subscale showed less than adequate reliability
scores, while the Rumination and Helplessness subscales were found to be reliable.
Osman and colleagues (2000) studied the validity of the PCS and found adequate
reliability (internal consistency) for all three subscales. The PCS can be used to track
negative automatic thoughts and pain cognitions.
Patient Health Questionnaire-9 (PHQ-9)
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The Patient Health Questionnaire-9 (PHQ-9) was used to assess depressive
symptoms. The PHQ-9 is a depression scale of a larger instrument called the Patient
Health Questionnaire (PHQ). The PHQ is a 3-page instrument that can be selfadministered by the patient. “The PHQ assesses 8 diagnoses, divided into threshold
disorders (disorders that correspond to specific DSM-IV diagnoses: major depressive
disorder, panic disorder, other anxiety disorder, and bulimia nervosa), and subthreshold
disorders (disorders who criteria encompass fewer symptoms than are required for any
specific DSM-IV diagnoses: other depressive disorder, probable alcohol
abuse/dependence, somatoform, and binge eating disorder).” (Kroenke, Spitzer, &
Williams, 2001, p. 606). The PHQ-9 scale is used to diagnose depressive disorders and
measure the severity of depressive symptoms (Kroenke, Spitzer, & Williams, 2001). The
PHQ-9 has 9-items that are based on the 9 criteria for depressive disorders identified in
the DSM-IV. Patients are asked how bothered they have been by 9 items in the past 2
weeks. They can choose from the following: Not at all (score-0), Several days (score-1),
More than half the days (score-2), and Nearly every day (score-3). The 9th-item is
particularly important as it addresses risk for suicide.

The total score for the PHQ-9

ranges from 0 to 27. Scores of 0 to 4 indicate no or minimal depression, 5 to 9 is mild
depression, 10 to 14 is moderate depression, 15 to 19 is moderately severe depression,
and scores above 20 are indicative of severe depression (PHQ instruction manual).
Kroenke and colleagues (2010) systematically reviewed the psychometric
characteristics of the Patient Health Questionnaire somatic, anxiety, and depression
scales. The PHQ-9 showed strong validity with sensitivity scores ranging from .77 to .88
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and specificity scores ranging from .88 to .94. Internal reliability ranged from .86 to .89
and test-retest reliability was .84. The area under the curve is .95 (Kroenke, et al., 2010).
Generalized Anxiety Disorder 7-Item Scale (GAD-7).
The Generalized Anxiety Disorder Scale is a 7-item scale that was originally
developed to diagnose generalized anxiety disorder but can also be used as a screener for
panic, social anxiety, and post-traumatic stress disorder (Kroenke et al., 2007). Patients
are asked to report how bothered they have been in the past 2 weeks by 7 items and the
responses are not at all, several days, more than half the days, and nearly every day. The
total score for the GAD-7 ranges from 0 to 21. Scores of 5, 10, and 15 represent cutoff
points for mild, moderate, and severe anxiety. A score of 10 or higher is the
recommended cutoff for further evaluation of anxiety symptoms.
The GAD-7 also showed strong psychometric properties (Kroenke, et al., 2010).
For identifying diagnostic criteria for generalized anxiety disorder, it showed a sensitivity
score of .89 and specificity score of .82. Additionally, the GAD-7 had strong sensitivity
and specificity scores for diagnosing panic (.74, .81), social anxiety (.72, .80), and posttraumatic stress disorder (.66, .81). The area under the curve was also high for
generalized anxiety disorder (.91), panic (.85), social anxiety (.83), and post-traumatic
stress disorder (.83).
Patient Health Questionnaire 15-Item Somatic Symptom Scale (PHQ-15)
The Patient Health Questionnaire 15-Item Somatic Symptom Scale is another
psychosocial assessment used at the pain management center where patient data were
collected and used in this study. This scale examines patient somatization. Patients are
asked to report how bothered they have been in the past 4 weeks by 15 somatic
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symptoms. The response choices include not bothered at all (0), bothered a little (1), and
bothered a lot (2) are added together providing a 0 to 30 somatic severity score. PHQ-15
scores of 5, 10, and 15 represent cutoff points for low, medium, and high somatization
(PHQ manual). For diagnosing somatoform disorders, the PHQ-15 showed a sensitivity
score of .78 and a specificity score of .71 (Kroenke, el al., 2010). Internal reliability was
.80 and test-restest reliability was .83. The area under the curve was .76 (Kroenke et al.,
2010).
Biofeedback Patient Report
In addition to the questions on the Independent Patient Report, each patient was
verbally asked to report their levels of pain and distress after the biofeedback training
session was completed using a numeric (0 to 10) rating scale. Clinicians record the
amount of time spent doing biofeedback training and the levels completed in the program
during each session. They also have the option to record any behavioral observations of
patients before, during, or after the biofeedback training session. Information related to
biofeedback in the dataset included pre-and post-intervention pain ratings, pre-and postintervention distress ratings, and number of biofeedback training sessions completed.
Patient Demographic and Health Information
Demographic information, health information, and information related to
biofeedback training was found in the electronic medical record used at the pain
management center. The following patient demographic information was obtained from
each study participant’s chart: gender; age; race/ethnicity/cultural background;
employment/disability status; educational achievement; marital status; number of
children; type of health insurance. Type of pain (musculoskeletal, neuropathic, and
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headache) and duration of pain (number of months/years) were also collected for this
study. Fibromyalgia has characteristics of both musculoskeletal pain and neuropathic
pain therefore it was categorized as both for this study. Headache diagnosis (migraine,
tension, or chronic daily type) conformed to the criteria of the International Headache
Society (International Classification of Headache Disorders-3 (ICHD-3); I, 2013).
Patient information regarding medications was not coded for use in this study.
Because patient medications tended to change frequently, coding either current or past
medication would not result in a useful variable for analysis in this study.
Similarly, many of the patients in this study had several different types of major
health conditions. The chronic pain population is often complicated medically.
Information on medical diagnoses, other than pain conditions, was not included because
some of the problem lists in the patient charts were quite extensive. It was unnecessary
to categorize other major health conditions to answer the study research questions.
Most patients who see pain psychology providers are given the same diagnosis:
adjustment reaction with mixed features of depression and anxiety. Some patients have
other mental health diagnoses in their chart but it could not be determined where these
diagnoses came from. Some clinicians enter mental health diagnoses based on patient
report and other mental health issues are diagnosed through extensive psychological
evaluation. Because it could not be established that mental health diagnoses were
clinician confirmed, the decision was made to not include mental health diagnoses as a
variable in the dataset. In addition, it was decided that history of mental health treatment
would not be included as a patient variable. Patient report of past mental health treatment
was inconsistent and differed greatly from patient to patient. Some patients reported a

76
history of mental health treatment from adolescence due to parental separation or divorce
and other patients had multiple psychiatric hospitalizations due to suicidal ideation. The
mental health treatment histories differed significantly; therefore dichotomous groupings
of “yes” or “no” could not be used to accurately categorize this type of patient
information. The same was true for history of trauma. The reported trauma histories
were also significantly different from patient to patient. Also, some patient’s pain
diagnoses were a result of trauma (e.g. back pain from a car accident) while other trauma
histories were from childhood. A logical categorizing method for types of traumas could
not be identified because patient histories were highly variable in terms of consistency.

Procedure
Data regarding the variables noted above were collected through an archival chart
review. The previously recorded data existed in the form of the patient electronic
medical record, results from diagnostic tests, and notes from health service providers
including a psychological evaluation. This archival chart review approach was conducted
taking into account the methodological weaknesses identified by Vassar and Holzman
(2013) that should be avoided when doing an archival or retrospective chart review study.
The present study had well-defined, clearly articulated research questions. In addition,
the treatment and forms were standardized and the types of patient data that were
collected for this archival study were identified prior to data collection.
Patients completed the Independent Patient Report received from the reception
team when the patient checked in for the biofeedback appointment. Biofeedback sessions
were usually conducted by an advanced practicum Ph.D. student under the supervision of
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the lead psychologist at the pain management center. Each biofeedback session was
approximately 45 to 60 minutes in duration. Biofeedback sessions were normally
scheduled 2 to 4 weeks apart.
Before each biofeedback session, patients were asked to report their current pain
rating using the numeric (0 to 10) rating scale and their current distress rating using a 0 to
10 scale. They also completed brief assessments of catastrophizing, depression, anxiety,
and somatization. After each biofeedback session, patients again reported their current
pain and distress levels using the 0 to 10 scale. Patients also had the opportunity to
describe their experience, and clinicians reported behavioral observations about the
participant during the biofeedback session. Those administering the biofeedback
program were trained on the procedure and treatment protocol by the advanced
psychology Ph.D. student (primary investigator) and the supervising lead psychologist.
Biofeedback Program
The Relaxing Rhythms guided training program from Wild Divine (now known as
Unyte Health Inc) includes a series of mindfulness-based exercises such as deep
breathing, guided imagery, and body scans. The primary objective is to quiet the mind,
release physical tension, and focus on the here-and-now. The training exercises and
activities used in the Relaxing Rhythms biofeedback program were developed with the
help of seven leading experts in the field of mindfulness and meditation: Zen Master
Nissim Amon, Dr. Dean Ornish, Dr. Andrew Weil, Joan Borysenko, Stephen Cope,
Nawang Khechog, and Sharon Salzberg.
The Relaxing Rhythms program includes the Iom biofeedback finger sensors that
detect two measures of physiological arousal within the body. These measures include
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skin conductance level (SCL) and heart rate variability (HRV). SCL and HRV are
associated with emotional arousal and autonomic nervous system activation. HRV is the
change in time intervals between heartbeats. Levels of skin conductance indicate the
body’s response to stress. Increased SCL are associated with increased stress while a
decreasing SCL represents a calming response. The Iom biofeedback finger sensors pick
up the body’s subtle changes in order to measure arousal.
In the HRV biofeedback program, patients participate in mindfulness-based
training activities and exercises, such as body scans, breathing exercises, and guided
imagery, and are given feedback on their physiological state. Patients can develop the
ability to control and alter their internal states using mindfulness and meditation-based
skills. Participants must be able to maintain a stable, balanced physiological state in
order to complete the exercise and move on to the next level of the program. Each level
targets a specific skill such as focusing on one’s breathing. Patients can complete one or
both guided training activities (e.g. deep breathing exercise) for each level. All training
activities are verbally guided by one of the mindful meditation experts who helped
develop the biofeedback program. Each program level also includes a practice event,
which is like a computer game that uses the body as the controller. For example, the first
level requires patients to maintain the heart breath, which is a pace of counting to 5 when
inhaling and exhaling. If the patients maintain steady breathing then a staircase bridge is
built and the patient successfully passes the practice event. Stairs appear on the screen
when the patient is in tune with the breathing tree that is guiding the pace. If the patient
is not breathing at a steady pace then the stairs will not appear. This type of feedback
encourages the patient to keep the slow steady rhythm of breath in order to completely
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build the staircase bridge. Each practice event requires patients to demonstrate different
skills using a fun, visually appealing game.
There are 15 levels that are divided into 3 parts. Part One is titled Self Discovery
and includes the following levels (1) Quiet Your Mind; (2) Observe Your Thoughts; (3)
Find Your Inner Balance; (4) Release Physical Tension; (5) Cultivate Positive Emotions;
and (6) Reveal Your Inner Wisdom. Part Two is called Creating Happiness and includes
(7) Subdue Your Inner Critic; (8) Open Yourself to Others; (9) Practice Compassion; (10)
Discover Gratitude; and (11) Connect to Something Outside of Yourself. Part Three of
the Relaxing Rhythms program is titled Develop Life Skills and its levels include (12) Set
Your Intentions; (13) Take a Daily Supplement; (14) Commit to a Personal Practice; and
(15) Find Your Rhythm. A patient’s advancement through the different levels of the
biofeedback program are tracked and recorded.
Relaxing Rhythms also has the Iom Grapher page that shows a patient’s heart
rate, coherence score, and average coherence score. Patients can observe how their
breathing affects these physiological measures in real time through the Iom Grapher.
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Chapter 4: Results
Correlation Analysis
A Pearson correlation analysis was done using SPSS statistical software to
investigate general trends and correlations in the data set. Correlations among the
symptom measures for Session 1 are presented in Table 4.1. The strongest relation
observed was between initial catastrophizing scores and anxiety scores, r(69) = 0.74, p <
.001, a level expected given the strong relationship between these two variables. The
second strongest correlation observed is between initial depression scores and anxiety
scores, r(69) = 0.68, p < .001. A moderately strong relation was observed between initial
catastrophizing scores and depression scores, r(69) = 0.52, p < .001. Initial somatization
scores had moderate correlations with initial depression scores, r(69) = 0.50, p < .001,
and initial anxiety scores, r(69) = 0.50, p < .001. There was a low to moderate
correlation between initial catastrophizing scores and somatization scores, r(69) = 0.32, p
= .006. The four mental health variables (catastrophizing, depression, anxiety, and
somatization) involve related concepts, but the moderate correlations among some of
them suggest they are measuring different symptomatology.
Moderately strong positive correlations were also observed between the mental
health variables and reported pain and distress scores. Initial catastrophizing scores were
moderately correlated with initial pre- and post-intervention pain ratings, r(69) = 0.49, p
< .001 and r(64) = 0.47, p < .001. A moderate relation was also observed between initial
depression scores and initial pre- and post-intervention pain ratings, r(69) = 0.42, p <
.001 and r(64) = 0.39, p = .001. For pre- and post-intervention pain ratings, the strongest
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correlation was found to be with anxiety, r(69) = 0.56, p < .001 and r(64) = 0.57, p <
.001. Somatization with pre- and post-intervention pain ratings had moderate
correlations, r(70) = 0.48, p < .001 and r(65) = 0.48, p < .001.
Correlations between the mental health variables and distress scores were slightly
more varied. Initial catastrophizing scores and pre- and post-intervention distress ratings
were moderately correlated, r(69) = 0.53, p < .001 and r(61) = 0.46, p < .001. A weaker
relation was observed, however, between initial depression scores and pre- and postintervention distress ratings, r(69) = 0.38, p = .001 and r(61) = .27, p = .030. As one
might expect, anxiety scores had the strongest relationship with pre- and postintervention distress ratings, r(69) = 0.66, p < .001; r(61) = 0.45, p < .001. Initial
somatization scores had a relatively weak correlation with pre- and post-intervention
distress ratings, r(70) = 0.35, p = .003 and r(62) = 0.30, p = .018.

Table 4.1. Correlations Between Symptom Variables at Session 1
S1PC S1PH S1GA S1PH S1Pai S1Pai S1Distr S1Distre
S
Q9
D7
Q15 nPre nPost essPre ssPost
S1PCS Pearson
1 .517** .737** .323** .490** .469**
.530**
.458**
Correlation
Sig. (2.000
.000 .006 .000 .000
.000
.000
tailed)
N
71
71
71
71
71
66
71
63
S1PHQ Pearson
.517**
1 .677** .499** .418** .393**
.382**
.274*
9
Correlation
Sig. (2.000
.000 .000 .000 .001
.001
.030
tailed)
N
71
71
71
71
71
66
71
63
S1GAD Pearson
.737** .677**
1 .499** .560** .572**
.661**
.453**
7
Correlation
Sig. (2.000 .000
.000 .000 .000
.000
.000
tailed)
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N
71
71
71
71
71
S1PHQ Pearson
.323** .499** .499**
1 .479**
15
Correlation
Sig. (2.006 .000
.000
.000
tailed)
N
71
71
71
72
72
S1Pain Pearson
.490** .418** .560** .479**
1
Pre
Correlation
Sig. (2.000 .000
.000 .000
tailed)
N
71
71
71
72
72
S1Pain Pearson
.469** .393** .572** .480** .856**
Post
Correlation
Sig. (2.000 .001
.000 .000 .000
tailed)
N
66
66
66
67
67
S1Distr Pearson
.530** .382** .661** .345** .747**
essPre Correlation
Sig. (2.000 .001
.000 .003 .000
tailed)
N
71
71
71
72
72
S1Distr Pearson
.458** .274* .453** .295* .572**
essPost Correlation
Sig. (2.000 .030
.000 .018 .000
tailed)
N
63
63
63
64
64
**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
PCS- Pain Catastrophizing Scale
PHQ9- Patient Health Questionnaire 9-Item
GAD7- Generalized Anxiety Disorder 7-Item
PHQ15- Patient Health Questionnaire 15-Item

66

71

63

.480**

.345**

.295*

.000

.003

.018

67

72

64

.856**

.747**

.572**

.000

.000

.000

67

72

64

1

.658**

.624**

.000

.000

67

67

64

.658**

1

.684**

.000

.000

67

72

64

.624**

.684**

1

.000

.000

64

64

64

Data Analysis Related to the Research Questions
Pre- and post-treatment pain and distress scores were examined in order to
address the study research question related to the effects of biofeedback training. Paired-
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sample t-tests were used to identify patient changes in pain, distress, catastrophizing,
depression, anxiety, and somatization over time. It was hypothesized that the
biofeedback training would reduce pain, distress, catastrophizing, depression, anxiety,
and somatization scores from the beginning of treatment to after three sessions.
Symptom improvement was defined by reductions in pain, distress, catastrophizing,
depression, anxiety, and somatization scores. A Bonferroni correction was used to adjust
for the family-wise error rate associated with the number of statistical tests performed.
Three t-tests were performed for each of the six research questions for a total of 18 tests.
Therefore, the p-value to suggest statistical significance was reduced from .05 to .0028
(i.e., .05/18=.0028).
Question 1. Does biofeedback training affect patient report of pain levels?
Using the numeric 0-10 self-report pain rating scale, the pre-intervention mean
score for Session 1 was 5.50 (SD = 2.55) and the post-intervention mean was 4.30 (SD =
2.59: see Table 4.2). For Session 2, the pre-intervention pain rating mean was 5.60 (SD =
2.49) and the post-intervention mean was 4.01 (SD = 2.59). The Session 3 preintervention mean was 5.65 (SD = 2.81) and the post-intervention mean was 4.24 (SD =
2.84). The decreases in levels of pain from pre-session to post-session were statistically
significant for Sessions 1, 2, and 3. As seen in Table 4.3, self-reported pain levels
dropped an average of 1.21 points after Session 1 of the biofeedback training, a
statistically significant difference of nearly one standard deviation (SD = 1.40), t(66) =
7.08, p < .001. The most improvement in pain ratings was seen after Session 2 with a
mean decrease of 1.63 points (SD = 1.96) after biofeedback, t(67) = 6.86, p < .001. After
Session 3, self-reported pain levels decreased an average of 1.50 points (SD = 1.68), t(67)
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= 7.37, p < .001. These statistically significant decreases in self-reported pain levels
show an overall effect of in-session pain relief.
What is noteable, however, is that the self-reported levels of pain did not drop
significantly across sessions. As indicated in Table 4.2, the mean pre-treatment pain
scores were essentially equivalent though there were negligible increases from Session 1
to Session 2 (.01 points), from Session 2 to Session 3 (0.06 points), and from Session 1 to
Session 3 (.07 points). There was a statistically significant decrease in the pain ratings
from Session 1 pre-treatment to Session 3 post-treatment, t(67) = 4.79, p < .001, showing
reductions in pain ratings from before treatment to after three sessions of biofeedback
training. Out of the 72 patients from this study who completed three sessions or more,
there were 39 patients who completed four sessions of biofeedback. There was a mean
1.67 decrease in pain ratings after Session 4 of biofeedback, t(38) = 5.992, p < .000.
However, those reductions were not maintained across sessions, resulting in a “sawtooth”
pattern of results (see Figure 4.1). Overall, the biofeedback training intervention
appeared to bring short-term pain relief within sessions, but that relief was not maintained
from session to session.

Table 4.2. Descriptive Statistics for Pain Scores
N Minimum Maximum Mean Std. Deviation
S1PainPre 72

.00

10.00 5.5000

2.54536

S1PainPost 67

.00

9.00 4.2985

2.59379

S2PainPre 71

.00

10.00 5.5915

2.48755

S2PainPost 68

.00

9.00 4.0147

2.59444

85
S3PainPre 71

.00

10.00 5.6479

2.80865

S3PainPost 68

.00

10.00 4.2353

2.83958

Table 4.3. T-Test Results for Pain Scores
Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Mean Deviation Mean Lower
Upper

t

Sig.
(2df tailed)

Pair S1PainPre 1
S1PainPost 1.20896

1.39845 .17085

.86785

1.55007 7.076 66

.000

Pair S2PainPre 2
S2PainPost 1.63235

1.96160 .23788 1.15754

2.10716 6.862 67

.000

Pair S3PainPre 3
S3PainPost 1.50000

1.67955 .20368 1.09346

1.90654 7.365 67

.000

Pair S1PainPre 4
S3PainPost 1.36765

2.35571 .28567

1.93785 4.787 67

.000

.79744
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Figure 4.1. Mean Pain Ratings
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Question 2. Does biofeedback training affect patient report of distress levels?
Using a 0-10 scale to rate distress levels, the mean reported level of distress for
Session 1 was 4.93 (SD = 2.71) pre-treatment and 3.22 (SD = 2.76) post-treatment. For
Session 2, the pre-treatment mean was 5.03 (SD = 2.59) and the post-treatment mean was
3.39 (SD = 2.56). At Session 3, the means were 5.18 (SD = 3.02) for pre-treatment and
3.61 (SD = 2.92) for post-treatment. The decrease in distress levels from pre-treatment to
post-treatment was statistically significant for Sessions 1, 2, and 3. Table 4.5 shows that
self-reported distress levels dropped 1.75 points (SD = 2.21) after Session 1 of the
biofeedback intervention, t(63) = 6.33, p < .001. At Session 2, there is a 1.67 point (SD =
2.10) difference between pre-treatment and post-treatment distress ratings, t(66) = 6.52, p
< .001. For Session 3, self-reported distress levels decreased 1.74 points (SD = 1.64)
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from pre-treatment to post-treatment, t(65) = 8.64, p < .001. These statistically
significant differences in distress ratings show an overall effect of distress relief during
each biofeedback session.
Distress ratings did not differ significantly across sessions either. In fact, the pretreatment distress scores increased slightly more than the pain pre-treatment scores. The
mean pre-treatment scores increased by .07 points from Session 1 to Session 2, .24 points
from Session 2 to Session 3, and .18 points from Session 1 to Session 3. However, there
was a statistically significant reduction in self-reported distress from the Session 1 pretreatment score to the Session 3 post-treatment score, t(65) = 4.69, p < .001. Similarly to
what was seen with pain ratings after Session 4 of biofeedback training, Session 4 also
had the largest decrease of patient reported distress ratings at an average of 2.46 points,
t(38) = 6.088, p < .000. The distress ratings also reveal a similar “sawtooth” pattern.
Again, this demonstrates that the biofeedback training intervention had statistically
significant improvements in distress ratings within sessions, but this relief was not
maintained over time from session to session.

Table 4.4. Descriptive Statistics for Distress Scores
N Minimum Maximum Mean Std. Deviation
S1DistressPre 72

.00

10.00 4.9306

2.70798

S1DistressPost 64

.00

10.00 3.2188

2.76296

S2DistressPre 71

.00

10.00 5.0282

2.58552

S2DistressPost 67

.00

9.00 3.3881

2.55814

88
S3DistressPre 71

.00

10.00 5.1831

3.02045

S3DistressPost 66

.00

10.00 3.6061

2.91879

Table 4.5. T-Test Results for Distress Scores
Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Mean Deviation Mean Lower Upper
Pair S1DistressPre
1.75000
1
S1DistressPost

t

Sig.
(2df tailed)

2.21108 .27639 1.19769 2.30231 6.332 63

.000

Pair S2DistressPre 1.67164
2
S2DistressPost

2.09898 .25643 1.15966 2.18362 6.519 66

.000

Pair S3DistressPre 1.74242
3
S3DistressPost

1.63905 .20175 1.33950 2.14535 8.636 65

.000

Pair S1DistressPre 1.54545
4
S3DistressPost

2.67859 .32971

.000

.88698 2.20393 4.687 65
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Figure 4.2. Mean Distress Ratings
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Question 3. Does biofeedback training affect patient catastrophizing scores?
Catastrophizing scores were obtained at the beginning of each session. Scores on
the Pain Catastrophizing Scale (PCS) can range from 0 to 52. For Session 1, the average
PCS score was 23.83 (SD = 12.59), for Session 2 the mean score was 22.48 (SD = 13.06),
and the mean PCS score for Session 3 was 21.15 (SD = 14.64). Analysis of these means
shows that biofeedback training significantly improved catastrophizing scores over time.
On average, catastrophizing scores were 1.68 points (SD = 6.65) lower for Session 2 than
for Session 1, t(68) = 2.10, p = .04. The most improvement is seen between the
catastrophizing scores from Session 1 and Session 3 with a decrease of 3.14 points (SD =
7.63) on the Pain Catastrophizing Scale, t(69) = 3.45, p = .001. Self-reported
catastrophizing scores were lowered from Session 2 to Session 3 by 1.32 points but this
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was not statistically significant, t(68) = 1.85, p = .069.

Table 4.6. Descriptive Statistics for Pain Catastrophizing Scores
N

Minimum

Maximum

Mean

Std. Deviation

S1PCS

71

.00

52.00

23.8310

12.59136

S2PCS

69

.00

52.00

22.4783

13.06388

S3PCS

71

.00

51.00

21.1549

14.63913

Table 4.7. T-Test Results for Pain Catastrophizing Scores

Mean
Pair S1PCS
1
S2PCS

Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Deviation
Mean
Lower
Upper

t

Sig. (2df tailed)

1.68116

6.65426

.80108

.08263

3.27969 2.099 68

.040

Pair S2PCS
2
S3PCS

1.31884

5.91979

.71266

-.10325

2.74093 1.851 68

.069

Pair S1PCS
3
S3PCS

3.14286

7.62963

.91191

1.32364

4.96208 3.446 69

.001

Question 4. Does biofeedback training affect patient depression scores?
Depression scores were obtained at the beginning of each session using the
Patient Health Questionnaire-9 (PHQ-9). In general, the range of scores for the PHQ-9 is
from 0 to 27. However, in this study, the highest score reported for Session 1 was 25, for
Session 2 was 25, and for Session 3 was 26. Session 1 had a mean depression score of
12.38 (SD = 5.84), Session 2 had a mean of 11.58 (SD = 6.12), and the mean PHQ-9

91
score for Session 3 was 11.60 (SD = 6.90). Self-reported depression scores decreased
slightly over the biofeedback training, but it was not a statistically significant decrease.
From Session 1 to Session 2, depression scores lowered 0.80 points (SD = 4.35) and from
Session 2 to Session 3 scores lowered 0.10 points (SD = 4.09). The most improvement is
seen when comparing Session 1 and Session 3 depression scores, which decreased .90
points (SD = 5.26). None of these reductions were statistically significant, however.

Table 4.8. Descriptive Statistics for Depression Scores
N Minimum Maximum

Mean

Std. Deviation

S1PHQ9 71

1.00

25.00 12.3803

5.84408

S2PHQ9 71

.00

25.00 11.5775

6.12177

S3PHQ9 72

.00

26.00 11.5972

6.90103

Table 4.9. T-Test Results for Depression Scores
Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Mean Deviation Mean
Lower
Upper
Pair S1PHQ9 .80282
1
S2PHQ9

t

Sig. (2df tailed)

4.35437

.51677

-.22785

1.83348 1.554 70

.125

Pair S2PHQ9 - .09859
2
S3PHQ9

4.08536

.48484

-.86840

1.06558

.203 70

.839

Pair S1PHQ9 - .90141
3
S3PHQ9

5.26214

.62450

-.34412

2.14694 1.443 70

.153

Question 5. Does biofeedback training affect patient anxiety scores?
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The Generalized Anxiety Disorder-7 scale (GAD-7) was administered at the
beginning of each session. Scores on the GAD-7 can range from 0 to 21. As seen in
Table 4.10, the mean anxiety score for Session 1 was 9.70 (SD = 5.43), for Session 2 was
8.99 (SD = 5.93), and for Session 3 was 9.56 (SD = 6.32). However, anxiety was not
statistically significantly reduced by the biofeedback training intervention (see Table
4.11). From Session 1 to Session 2, the anxiety scores decreased .67 points (SD = 3.82)
and from Session 1 to Session 3, anxiety scores decreased .21 points (SD = 4.66) on the
GAD-7. However, from Session 2 to Session 3, the anxiety scores actually went up .39
points (SD = 4.30).

Table 4.10. Descriptive Statistics for Anxiety Scores
N Minimum Maximum Mean Std. Deviation
S1GAD7 71

.00

21.00 9.7042

5.43374

S2GAD7 70

.00

21.00 8.9857

5.92830

S3GAD7 72

.00

21.00 9.5556

6.32208

Table 4.11. T-Test Results for Anxiety Scores
Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Mean Deviation Mean
Lower
Upper
Pair S1GAD7
1
S2GAD7
Pair S2GAD7
2
S3GAD7

.67143
-.38571

3.82108 .45671

t

Sig.
(2df tailed)

-.23967

1.58253 1.470 69

.146

4.30131 .51410 -1.41132

.63990 -.750 69

.456
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Pair S1GAD7
3
S3GAD7

.21127

4.66266 .55336

-.89237

1.31490

.382 70

.704

Question 6. Does biofeedback training affect patient somatization scores?
The Patient Health Questionnaire-15 (PHQ-15) was administered at the beginning
of each session to measure somatization. The highest possible score on the PHQ-15 is
30. However, the highest reported somatization score for the patients was 24 for Session
1, 24 for Session 2, and 25 for Session 3. Session 1 had a mean PHQ-15 score of 12.68
(SD = 5.55), for Session 2 the mean score was 12.13 (SD = 5.80), and the mean
somatization score for Session 3 was 12.50 (SD = 6.09). Somatization scores were not
significantly affected by the biofeedback training intervention. From Session 1 to
Session 2, somatization scores decreased by .47 points (SD = 2.81) and from Session 1 to
Session 3, somatization scores decreased by .18 points (SD = 2.70) on the PHQ15.
However, somatization scores increased .26 points (SD = 2.42) from Session 2 to Session
3.

Table 4.12. Descriptive Statistics for Somatization Scores
N Minimum Maximum

Mean

Std. Deviation

S1PHQ15 72

3.00

24.00 12.6806

5.55086

S2PHQ15 70

1.00

24.00 12.1286

5.79585

S3PHQ15 72

.00

25.00 12.5000

6.08855

Table 4.13. T-Test Results for Somatization Scores
Paired Differences
t

df

Sig.
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Mean
Pair S1PHQ15
1
S2PHQ15

Std.
Deviation

Std.
Error
Mean

95% Confidence
Interval of the
Difference
Lower
Upper

(2tailed)

.47143

2.81158 .33605 -.19897

1.14183 1.403 69

.165

Pair S2PHQ15
2
S3PHQ15

-.25714

2.41784 .28899 -.83366

.31937 -.890 69

.377

Pair S1PHQ15
3
S3PHQ15

.18056

2.69755 .31791 -.45334

.81445

.572

.568 71

Post Hoc Analyses
Given the lack of sustained improvement in pain and distress relief across
sessions and the wide variability found in the symptom scores across patients, a series of
more detailed post hoc analyses was performed. To explore the possibility that those
with high catastrophizing, depression, anxiety, or somatization scores responded
differently to the mindfulness-based biofeedback intervention than those with lower
symptomatology on these variables, a follow-up analysis was conducted after splitting the
patients into tertiles (i.e., roughly equal size groups with high, medium, and low symptom
scores).
Catastrophizing Groups
In order to compare patients with high, medium, and low catastrophizing
tendencies, the participants were divided into three groups based on their initial
catastrophizing scores. The first third (n=22) had the lowest catastrophizing scores,
which ranged from 0-16 (M = 10.14, SD = 4.37), the middle third (n=24) had
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catastrophizing scores from 17-28 (M = 21.79, SD = 3.81), and the last third (n=25) had
the highest catastrophizing scores ranging from 29-52 (M = 37.84, SD = 7.16).

Table 4.14. Descriptive Statistics for Catastrophizing Groups
Group

N

Range Mean (Standard Deviation)

Low Catastrophizing

22 0-16

10.14 (4.37)

Medium Catastrophizing 24 17-28

21.79 (3.81)

High Catastrophizing

37.84 (7.16)

25 29-52

Session 1 pre- and post-intervention pain ratings differed significantly between
the three catastrophizing groups, F(2,68) = 9.56, p < .001; F(2,63) = 6.77, p = .002. For
the low catastrophizing group, the mean pre-intervention pain rating for Session 1 was
4.14 and the mean post-intervention pain rating was 3.05 showing a 1.09 point decrease
in pain ratings after the biofeedback intervention. The medium catastrophizing group had
a pre-intervention pain rating mean of 5.08 and post-intervention mean of 3.87, which
shows a 1.21 decrease in pain ratings after biofeedback training for Session 1. The
average pre-intervention pain rating score for the high catastrophizing group was 6.96
and the average post-intervention pain rating score was 5.61. This group showed the
greatest decrease in pain ratings with a 1.35 point decrease after the biofeedback
intervention for Session 1. For Session 2, the pre-intervention pain ratings differed
significantly between the three catastrophizing groups, F(2,67) = 8.38, p = .001.
However, the post-intervention ratings for Session 2 were not significantly different
between the three catastrophizing groups, F(2,64) = 2.18, p = .121. For Session 2, the
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mean pre-intervention pain rating for the low catastrophizing group was 4.52, for the
medium catastrophizing group was 4.92, and for the high catastrophizing group was 7.00.
The low catastrophizing group had a mean post-intervention pain rating score of 3.50, the
medium catastrophizing had a mean score of 3.43, and the high catastrophizing group had
a mean pain rating of 4.79 after the biofeedback intervention in Session 2. This shows an
average decrease of 1.02 for the low catastrophizing group, 1.49 for the medium
catastrophizing group, and 2.21 for the high catastrophizing group. Session 3 pre- and
post-intervention pain ratings differed significantly between the three catastrophizing
groups, F(2, 67) = 9.42, p < .001; F(2, 64) = 8.12, p = .001. For the low catastrophizing
group, the pre-intervention mean pain rating score for Session 3 was 4.19 and the mean
post-intervention pain rating score was 3.10 which is a decrease of 1.09 in pain ratings
after the biofeedback intervention. The medium catastrophizing group had a preintervention average pain rating score of 5.08 and post-intervention average pain rating
score of 3.42 showing a reduction in self-reported pain ratings of 1.66 points. In the high
catastrophizing group, the mean pre-intervention pain rating was 7.28 and the mean postintervention pain rating was 5.91, which shows a 1.37 decrease in pain ratings after the
biofeedback training. The “sawtooth” pattern seen with the total group’s pain ratings is
also apparent with the mean pain ratings of all three catastrophizing groups.

Table 4.15. Pain Scores of Low, Medium, and High Catastrophizing Groups
95%
Confidence
Low (1),
Interval for
Medium (2), and
Mean
Std.
High (3)
Deviatio Std. Lower Upper Minimu Maximu
Catastrophizing
Groups
N Mean
n
Error Bound Bound
m
m
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S1PainPre 1.00
2.00
3.00
Tota
l
S1PainPos 1.00
t
2.00
3.00
Tota
l
S2PainPre 1.00
2.00
3.00
Tota
l
S2PainPos 1.00
t
2.00
3.00
Tota
l
S3PainPre 1.00
2.00
3.00

2
2
2
4
2
5
7
1
2
0
2
3
2
3
6
6
2
1
2
4
2
5
7
0
2
0
2
3
2
4
6
7
2
1
2
4
2
5

4.136
4
5.083
3
6.960
0
5.450
7
3.050
0
3.869
6
5.608
7
4.227
3
4.523
8
4.916
7
7.000
0
5.542
9
3.500
0
3.434
8
4.791
7
3.940
3
4.190
5
5.083
3
7.280
0

2.81654
2.14510
1.79072
2.52863
2.41650
2.45513
2.16877
2.54677
2.54203
2.18526
2.02073
2.47120
2.70477
2.19143
2.58725
2.53987
2.63854
2.39414
2.50865

.6004
9
.4378
7
.3581
4
.3000
9
.5403
5
.5119
3
.4522
2
.3134
9
.5547
2
.4460
6
.4041
5
.2953
6
.6048
1
.4569
5
.5281
2
.3102
9
.5757
8
.4887
0
.5017
3

2.887
6
4.177
5
6.220
8
4.852
2
1.919
0
2.807
9
4.670
8
3.601
2
3.366
7
3.993
9
6.165
9
4.953
6
2.234
1
2.487
1
3.699
2
3.320
8
2.989
4
4.072
4
6.244
5

5.385
1
5.989
1
7.699
2
6.049
2
4.181
0
4.931
2
6.546
5
4.853
3
5.680
9
5.839
4
7.834
1
6.132
1
4.765
9
4.382
4
5.884
2
4.559
8
5.391
5
6.094
3
8.315
5

.00

8.00

.00

9.00

4.00

10.00

.00

10.00

.00

7.00

.00

8.00

.00

9.00

.00

9.00

.00

8.00

.00

8.00

2.00

10.00

.00

10.00

.00

8.00

.00

8.00

.00

9.00

.00

9.00

.00

8.00

.00

10.00

.00

10.00
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Tota
l
S3PainPos 1.00
t
2.00
3.00
Tota
l

7
0
2
0
2
4
2
3
6
7

5.600
0
3.100
0
3.416
7
5.913
0
4.179
1

2.79959
2.61373
2.35753
2.71215
2.82266

.3346
1
.5844
5
.4812
3
.5655
2
.3448
4

4.932
5
1.876
7
2.421
2
4.740
2
3.490
6

6.267
5
4.323
3
4.412
2
7.085
9
4.867
6

.00

10.00

.00

7.00

.00

8.00

.00

10.00

.00

10.00

Table 4.16. Pain Score Differences Between Catastrophizing Groups
Sum of Squares df Mean Square F Sig.
S1PainPre Between Groups
98.193 2
49.097 9.556 .000
Within Groups
349.384 68
5.138
Total
447.577 70
S1PainPost Between Groups
74.554 2
37.277 6.767 .002
Within Groups
347.037 63
5.509
Total
421.591 65
S2PainPre Between Groups
84.300 2
42.150 8.378 .001
Within Groups
337.071 67
5.031
Total
421.371 69
S2PainPost Between Groups
27.151 2
13.575 2.180 .121
Within Groups
398.611 64
6.228
Total
425.761 66
S3PainPre Between Groups
118.689 2
59.344 9.419 .000
Within Groups
422.111 67
6.300
Total
540.800 69
S3PainPost Between Groups
106.391 2
53.196 8.116 .001
Within Groups
419.459 64
6.554
Total
525.851 66
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Figure 4.3 Pain Ratings of Low, Medium, and High
Catastrophizing Groups
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A similar pattern was found for the distress ratings and the three catastrophizing
groups. Session 1 pre- and post-intervention distress ratings differed significantly
between the three groups, F(2,68) = 9.31, p < .001; F(2,60) = 7.54, p = .001. The low
catastrophizing group had a pre-intervention mean distress rating of 3.68 and a postintervention mean distress rating of 2.42 showing a 1.26 decrease in reported distress
ratings. The medium catastrophizing group had an average distress rating of 4.25 before
biofeedback training and 2.17 after biofeedback training, which shows a 2.08 point
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reduction in reported distress ratings. The high catastrophizing group had a preintervention mean distress score of 6.52 and a post-intervention mean distress score of
4.81, which is a 1.71 point decrease in reported distress for Session 1. The three
catastrophizing groups also had significantly different pre- and post-intervention distress
ratings for Session 2, F(2,67) = 8.83, p < .001; F(2,63) = 5.56, p = .006. For the low
catastrophizing group, the mean pre-intervention distress rating was 3.95 and the mean
post-intervention distress rating was 2.84 showing a 1.11 point decrease in distress
ratings. The medium catastrophizing group had an average distress score of 4.25 preintervention and 2.39 post-intervention, which shows a 1.86 reduction in reported
distress. The high catastrophizing group had a mean pre-intervention rating of 6.52 and a
mean post-intervention rating of 4.54 showing a 1.98 decrease in distress. For Session 3,
the three catastrophizing groups’ scores were also significantly different for both preintervention and post-intervention ratings, F(2,67) = 9.001, p < .001; F(2,62) = 10.868, p
< .001. The low catastrophizing group mean pre-intervention rating was 3.90 and their
mean post-intervention rating was 2.78, which is a 1.12 point decrease. For the medium
catastrophizing group, the mean pre-intervention distress rating was 4.29 and the mean
post-intervention distress rating was 2.25 showing a 2.04 point reduction. The high
catastrophizing group had a mean distress rating of 6.96 pre-intervention and 5.52 postintervention, which shows a 1.44 point decrease in reported distress levels. Again, a
familiar “sawtooth” pattern can be observed with the distress ratings for all three
catastrophizing groups.

Table 4.17. Distress Scores of Low, Medium, and High Catastrophizing Groups
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Low (1),
Medium (2), and
Std.
High (3)
Deviatio Std.
Catastrophizing
Groups
N Mean
n
Error
S1DistressPre 1.00 2 3.681
.5899
2.76692
2
8
1
2.00 2 4.250
.4594
2.25060
4
0
0
3.00 2 6.520
.4439
2.21961
5
0
2
Tota 7 4.873
.3184
2.68291
l
1
2
0
S1DistressPos 1.00 1 2.421
.5738
2.50146
t
9
1
7
2.00 2 2.173
.4855
2.32872
3
9
7
3.00 2 4.809
.5460
2.50238
1
5
6
Tota 6 3.127
.3382
2.68504
l
3
0
8
S2DistressPre 1.00 2 3.952
.5751
2.63583
1
4
9
2.00 2 4.250
.4672
2.28891
4
0
2
3.00 2 6.520
.4046
2.02320
5
0
4
Tota 7 4.971
.3058
2.55928
l
0
4
9
S2DistressPos 1.00 1 2.842
.5475
2.38661
t
9
1
3
2.00 2 2.391
.4343
2.08325
3
3
9
3.00 2 4.541
.5071
2.48437
4
7
2

95%
Confidence
Interval for
Mean
Lowe
r
Upper
Boun Boun Minimu Maximu
d
d
m
m
2.455 4.908
.00
9.00
0
6
3.299 5.200
.00
9.00
7
3
5.603 7.436
2.00
10.00
8
2
4.238 5.508
.00
10.00
2
3
1.215 3.626
.00
6.00
4
7
1.166 3.180
.00
7.00
9
9
3.670 5.948
.00
10.00
5
6
2.450 3.803
.00
10.00
8
2
2.752 5.152
.00
9.00
6
2
3.283 5.216
.00
9.00
5
5
5.684 7.355
2.00
10.00
9
1
4.361 5.581
.00
10.00
2
7
1.691 3.992
.00
8.00
8
4
1.490 3.292
.00
7.00
4
2
3.492 5.590
.00
8.00
6
7
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Tota
l
S3DistressPre 1.00
2.00
3.00
Tota
l
S3DistressPos 1.00
t
2.00
3.00
Tota
l

6
6
2
1
2
4
2
5
7
0
1
8
2
4
2
3
6
5

3.303
0
3.904
8
4.291
7
6.960
0
5.128
6
2.777
8
2.250
0
5.521
7
3.553
8

2.48051
3.41913
2.11576
2.54100
3.00686
2.88109
2.17196
2.62626
2.91028

.3053
3
.7461
2
.4318
8
.5082
0
.3593
9
.6790
8
.4433
5
.5476
1
.3609
8

2.693
2
2.348
4
3.398
3
5.911
1
4.411
6
1.345
0
1.332
9
4.386
1
2.832
7

3.912
8
5.461
1
5.185
1
8.008
9
5.845
5
4.210
5
3.167
1
6.657
4
4.275
0

.00

8.00

.00

10.00

.00

9.00

.00

10.00

.00

10.00

.00

9.00

.00

6.00

.00

10.00

.00

10.00

Table 4.18. Distress Score Differences Between Catastrophizing Groups
Sum of Squares df Mean Square
F
Sig.
S1DistressPre Between Groups
108.346 2
54.173 9.314 .000
Within Groups
395.513 68
5.816
Total
503.859 70
S1DistressPost Between Groups
89.810 2
44.905 7.543 .001
Within Groups
357.174 60
5.953
Total
446.984 62
S2DistressPre Between Groups
94.250 2
47.125 8.827 .000
Within Groups
357.692 67
5.339
Total
451.943 69
S2DistressPost Between Groups
59.976 2
29.988 5.557 .006
Within Groups
339.963 63
5.396
Total
399.939 65
S3DistressPre Between Groups
132.115 2
66.058 9.001 .000
Within Groups
491.728 67
7.339
Total
623.843 69
S3DistressPost Between Groups
140.711 2
70.356 10.868 .000
Within Groups
401.350 62
6.473
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542.062 64

Figure 4.4. Distress Ratings of Low, Medium, and
High Catastrophizing Groups
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Depression Groups
The dataset was also divided into three groups based on initial depression scores
(see Table 4.18). The first group (n=20) had the lowest depression scores ranging from
0-8 (M = 5.25, SD = 2.40). The middle group (n=27) had depression scores in the midrange 9-15 (M = 11.89, SD = 1.91). The third group (n=24) had the highest depression
scores ranging from 16-25 (M = 18.88, SD = 2.56).
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Table 4.19. Descriptive Statistics for Depression Groups
Group

N

Range Mean (Standard Deviation)

Low Depression

20 0-8

5.25 (2.40)

Medium Depression 27 9-15

11.89 (1.91)

High Depression

18.88 (2.56)

24 16-25

Session 1 pre- and post-intervention pain ratings were significantly different
between the three depression groups, F(2,68) = 4.85, p = .011; F(2,63) = 4.37, p = .017.
For the low depression group, the average pre-intervention pain rating for Session 1 was
4.05 and the average post-intervention pain rating was 2.84 showing a 1.21 point
decrease in pain ratings after the biofeedback training. The medium depression group
had a pre-intervention mean pain rating of 5.85 and post-intervention pain rating of 4.73,
which is a 1.12 point pain reduction. The pre-intervention mean pain rating was 6.17 and
the post-intervention pain rating was 4.86 showing a 1.31 point decrease in pain for the
high depression group. For Session 2, there were also significant differences observed
between the three depression groups for the pre-and post-intervention pain ratings, F(2,
67) = 5.60, p = .006; F(2,67) = 4.96, p = .010. The low depression group had a preintervention mean pain score of 4.20 and a post-intervention mean pain score of 2.47,
which is a 1.73 point reduction in reported pain levels. For the middle depression group,
the mean pre-intervention pain rating was 5.65 and the mean post-intervention pain rating
was 4.56 showing a 1.09 point decrease in pain ratings. The high depression group had a
mean pre-intervention pain rating score of 6.54 and a mean post-intervention pain rating
score of 4.48, which is a 2.06 reduction in patient-reported pain levels. Session 3 also

105
had a statistically significant difference between the three depression group means for
pre- and post-intervention pain ratings, F(2,67) = 4.08, p = .021; F(2,64) = 4.43, p = .016.
The low depression group had a pre-intervention mean pain rating of 4.11 and a postintervention mean pain rating of 2.63 showing a 1.48 reduction. The middle depression
group’s pre-intervention average pain rating was 6.07 and their post-intervention pain
rating was 4.88, which is a 1.19 decrease in pain. For the high depression group, the
mean pre-intervention pain score was 6.25 and the post-intervention pain score was 4.70
showing a 1.55 point decrease in reported pain levels after the biofeedback training. The
mean pain ratings for the three depression groups also had a “sawtooth” pattern.

Table 4.20. Pain Scores of Low, Medium, and High Depression Groups
95%
Confidence
Low (1),
Interval for
Medium (2), and
Mean
Std.
High (3)
Deviatio Std. Lower Upper Minimu Maximu
Depression
Groups
N Mean
n
Error Bound Bound
m
m
S1PainPre 1.00 2 4.050
.6218 2.748 5.351
2.78104
.00
8.00
0
0
6
4
6
2.00 2 5.851
.4582 4.909 6.793
2.38107
.00
10.00
7
9
4
9
8
3.00 2 6.166
.4199 5.298 7.035
2.05715
.00
10.00
4
7
1
0
3
Tota 7 5.450
.3000 4.852 6.049
2.52863
.00
10.00
l
1
7
9
2
2
S1PainPos 1.00 1 2.842
.5201 1.749 3.934
2.26723
.00
8.00
t
9
1
4
3
9
2.00 2 4.730
.5009 3.699 5.762
2.55433
.00
9.00
6
8
5
1
5
3.00 2 4.857
.5222 3.767 5.946
2.39344
.00
8.00
1
1
9
7
6

106
Tota
l
S2PainPre 1.00
2.00
3.00
Tota
l
S2PainPos 1.00
t
2.00
3.00
Tota
l
S3PainPre 1.00
2.00
3.00
Tota
l
S3PainPos 1.00
t
2.00
3.00
Tota
l

6
6
2
0
2
6
2
4
7
0
1
9
2
5
2
3
6
7
1
9
2
7
2
4
7
0
1
9
2
5
2
3
6
7

4.227
3
4.200
0
5.653
8
6.541
7
5.542
9
2.473
7
4.560
0
4.478
3
3.940
3
4.105
3
6.074
1
6.250
0
5.600
0
2.631
6
4.880
0
4.695
7
4.179
1

2.54677
2.68720
2.29682
1.99955
2.47120
2.26981
2.38188
2.52027
2.53987
2.70585
2.96033
2.30783
2.79959
2.21637
3.23161
2.36326
2.82266

.3134
9
.6008
8
.4504
4
.4081
6
.2953
6
.5207
3
.4763
8
.5255
1
.3102
9
.6207
7
.5697
2
.4710
8
.3346
1
.5084
7
.6463
2
.4927
7
.3448
4

3.601
2
2.942
4
4.726
1
5.697
3
4.953
6
1.379
7
3.576
8
3.388
4
3.320
8
2.801
1
4.903
0
5.275
5
4.932
5
1.563
3
3.546
1
3.673
7
3.490
6

4.853
3
5.457
6
6.581
6
7.386
0
6.132
1
3.567
7
5.543
2
5.568
1
4.559
8
5.409
4
7.245
1
7.224
5
6.267
5
3.699
8
6.213
9
5.717
6
4.867
6

.00

9.00

.00

8.00

1.00

10.00

2.00

10.00

.00

10.00

.00

6.00

.00

9.00

.00

8.00

.00

9.00

.00
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.00
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Table 4.21. Pain Score Differences Between Depression Groups
Sum of Squares df Mean Square F Sig.
S1PainPre Between Groups
55.887 2
27.943 4.851 .011
Within Groups
391.691 68
5.760
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S1PainPost

S2PainPre

S2PainPost

S3PainPre

S3PainPost

Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total

447.577
51.378
370.213
421.591
60.328
361.043
421.371
57.125
368.636
425.761
58.659
482.141
540.800
63.920
461.931
525.851

70
2
63
65
2
67
69
2
64
66
2
67
69
2
64
66

25.689 4.372 .017
5.876
30.164 5.598 .006
5.389
28.563 4.959 .010
5.760
29.329 4.076 .021
7.196
31.960 4.428 .016
7.218
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Figure 4.5. Pain Ratings of Low, Medium, and
High Depression Groups
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The distress scores of the three depression groups were also compared and several
statistically significant differences were found. For Session 1, the pre-intervention
distress ratings were significantly different, F(2,68) = 3.58, p = .033, but the difference in
post-intervention distress ratings was not statistically significant, F(2,60) = 1.43, p =
.248. The group with the lowest depression scores had a pre-intervention mean distress
score of 3.60 and a post-intervention distress score mean of 2.39 showing a 1.21 point
decrease in distress. For the middle depression group, the pre-intervention mean distress
score was 5.15 and the post-intervention mean distress score was 3.08, which is a 2.07
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point reduction in distress. The high depression group’s mean pre-intervention distress
rating was 5.63 and their mean post-intervention distress rating was 3.85 showing a 1.78
decrease in distress scores after the biofeedback intervention. For Session 2, there were
statistically significant differences between depression groups for both the pre- and postintervention distress ratings, F(2,67) = 5.35, p = .007; F(2,63) = 5.55, p = .006. The
average pre-intervention distress score for the low depression group was 3.50 and 1.89
for their average post-intervention distress score, which shows a 1.61 point reduction.
For the middle depression group, the mean pre-intervention distress score was 5.73 and
the mean post-intervention distress score was 4.25 showing a 1.48 point decrease in
distress scores. The high depression group had a pre-intervention mean distress score of
5.38 and post-intervention mean distress score of 3.48, which is a 1.9 point reduction in
reported distress ratings after the biofeedback training. There were significant
differences between depression groups for the pre- and post-intervention distress ratings
for Session 3, F(2,67) = 4.99, p = .010; F(2,62) = 6.61, p = .003. The low depression
group’s pre-intervention mean distress score was 3.37 and their post-intervention mean
distress score was 1.61 showing a 1.76 point difference. The middle depression group
had a pre-intervention mean distress score of 5.74 and post-intervention mean distress
score of 4.46, which shows a 1.28 point reduction in distress ratings. For the high
depression group, the pre-intervention mean distress rating was 5.83 and the postintervention mean distress rating was 4.13, which is a 1.7 point decrease in reported
distress scores. The distress scores for the three depression groups also showed a
“sawtooth” pattern.

110
Table 4.22. Distress Scores of Low, Medium, and High Depression Groups
95% Confidence
Low (1),
Interval for
Medium (2), and
Mean
High (3)
Std.
Std.
Lower Upper Minimu
Depression
Groups
N Mean Deviation Error Bound Bound
m
Maximum
S1Distress 1.00
20 3.6000 2.96293 .66253 2.2133 4.9867
.00
9.00
Pre
2.00
27 5.1481 2.47610 .47653 4.1686 6.1277
1.00
10.00
3.00
24 5.6250 2.37400 .48459 4.6225 6.6275
.00
10.00
Total
71 4.8732 2.68291 .31840 4.2382 5.5083
.00
10.00
S1Distress 1.00
18 2.3889 2.56994 .60574 1.1109 3.6669
.00
7.00
Post
2.00
25 3.0800 2.78268 .55654 1.9314 4.2286
.00
10.00
3.00
20 3.8500 2.60111 .58163 2.6326 5.0674
.00
8.00
Total
63 3.1270 2.68504 .33828 2.4508 3.8032
.00
10.00
S2Distress 1.00
20 3.5000 2.96470 .66293 2.1125 4.8875
.00
9.00
Pre
2.00
26 5.7308 2.23710 .43873 4.8272 6.6344
2.00
10.00
3.00
24 5.3750 2.06023 .42054 4.5050 6.2450
2.00
10.00
Total
70 4.9714 2.55928 .30589 4.3612 5.5817
.00
10.00
S2Distress 1.00
19 1.8947 2.10541 .48301 .8800 2.9095
.00
8.00
Post
2.00
24 4.2500 2.43614 .49728 3.2213 5.2787
.00
8.00
3.00
23 3.4783 2.37160 .49451 2.4527 4.5038
.00
7.00
Total
66 3.3030 2.48051 .30533 2.6932 3.9128
.00
8.00
S3Distress 1.00
19 3.3684 2.87152 .65877 1.9844 4.7524
.00
8.00
Pre
2.00
27 5.7407 2.79550 .53799 4.6349 6.8466
.00
10.00
3.00
24 5.8333 2.88424 .58874 4.6154 7.0512
.00
10.00
Total
70 5.1286 3.00686 .35939 4.4116 5.8455
.00
10.00
S3Distress 1.00
18 1.6111 2.03322 .47923 .6000 2.6222
.00
6.00
Post
2.00
24 4.4583 3.06423 .62548 3.1644 5.7522
.00
10.00
3.00
23 4.1304 2.70192 .56339 2.9620 5.2988
.00
9.00
Total
65 3.5538 2.91028 .36098 2.8327 4.2750
.00
10.00

Table 4.23. Distress Score Differences Between Depression Groups
Sum of Squares df Mean Square F Sig.
S1DistressPre Between Groups
48.027 2
24.013 3.582 .033
Within Groups
455.832 68
6.703
Total
503.859 70
S1DistressPost Between Groups
20.316 2
10.158 1.428 .248
Within Groups
426.668 60
7.111
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S2DistressPre

S2DistressPost

S3DistressPre

S3DistressPost

10

Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total

446.984
62.202
389.740
451.943
59.911
340.029
399.939
80.903
542.940
623.843
95.217
446.845
542.062

62
2
67
69
2
63
65
2
67
69
2
62
64

31.101 5.347 .007
5.817
29.955 5.550 .006
5.397
40.452 4.992 .010
8.104
47.608 6.606 .003
7.207

Figure 4.6. Distress Ratings for Low, Medium, and
High Depression Groups
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Anxiety Groups
The dataset was again divided into thirds based on anxiety scores. The first group
(n=22) had the lowest anxiety scores, which ranged from 0-5 (M = 3.00, SD = 1.57). The
second group (n=16) had anxiety scores in the middle ranging from 6-11 (M = 9.06, SD =
1.84). The last group (n=33) had anxiety scores of 12 to 21 (M = 14.48, SD = 2.59).

Table 4.24. Descriptive Statistics for Anxiety Groups
Group

N

Range Mean (Standard Deviation)

Low Anxiety

22 0-5

3.00 (1.57)

Medium Anxiety 16 6-11

9.06 (1.84)

High Anxiety

14.48 (2.59)

33 12-21

Session 1 pre- and post-intervention pain ratings had statistically significant
differences between the anxiety groups, F(2,68) = 15.46, p < .000; F(2,63) = 14.07, p <
.000. For the low anxiety group, the pre-intervention mean pain rating for Session 1 was
3.91 and the post-intervention mean pain rating was 2.57, which is a 1.34 point decrease
in pain ratings. The medium anxiety group had a pre-intervention average pain rating of
4.50 and a post-intervention average pain rating of 3.50 showing a 1.0 point decrease in
pain. The high anxiety group’s pre-intervention mean pain score was 6.94 and their postintervention mean pain score was 5.68, which shows a 1.26 point decrease in reported
pain ratings after the biofeedback intervention. There were significant differences
between the pre- and post-intervention pain ratings of the three anxiety groups for
Session 2 as well, F(2,67) = 11.62, p < .000; F(2,64) = 3.63, p = .032. For the low

113
anxiety group, the mean pre-intervention pain rating was 4.18 and the mean postintervention pain rating was 2.95 showing a 1.23 point reduction in pain ratings after the
biofeedback session. The medium anxiety group had an average pre-intervention pain
rating of 4.67 and an average post-intervention pain rating of 3.57, which is a 1.1 point
decrease. The high anxiety group had a pre-intervention mean pain rating of 6.85 and a
post-intervention mean pain rating of 4.75 showing a 2.1 point reduction in pain scores.
The pre- and post-intervention pain ratings for Session 3 were also significantly different
between the three anxiety groups, F(2,67) = 7.89, p = .001; F(2,64) = 4.40, p = .016. For
the low anxiety group, the pre-intervention mean pain rating was 4.14 and the postintervention mean pain rating was 3.00, which is a 1.14 point decrease. The medium
anxiety group had a pre-intervention mean pain rating of 4.94 and a post-intervention
mean pain rating of 3.69 showing a 1.25 point reduction in pain. For the high anxiety
group, the pre-intervention mean pain rating was 6.85 and the post-intervention mean
pain rating was 5.19, which is a 1.66 point reduction in reported pain levels. A similar
“sawtooth” pattern is seen with the pain scores of all three anxiety groups.

Table 4.25. Pain Scores of Low, Medium, and High Anxiety Groups
95%
Confidence
Low (1),
Interval for
Medium (2), and
Mean
Std.
High (3)
Deviatio Std. Lower Upper Minimu Maximu
Anxiety
Groups
N Mean
n
Error Bound Bound
m
m
S1PainPre 1.00 2 3.909
.5218 2.823 4.994
2.44772
.00
8.00
2
1
6
8
3
2.00 1 4.500
.6582 3.096 5.903
2.63312
.00
9.00
6
0
8
9
1

114
3.00
Tota
l
S1PainPos 1.00
t
2.00
3.00
Tota
l
S2PainPre 1.00
2.00
3.00
Tota
l
S2PainPos 1.00
t
2.00
3.00
Tota
l
S3PainPre 1.00
2.00
3.00
Tota
l
S3PainPos 1.00
t

3
3
7
1
2
1
1
4
3
1
6
6
2
2
1
5
3
3
7
0
2
1
1
4
3
2
6
7
2
1
1
6
3
3
7
0
2
0

6.939
4
5.450
7
2.571
4
3.500
0
5.677
4
4.227
3
4.181
8
4.666
7
6.848
5
5.542
9
2.952
4
3.571
4
4.750
0
3.940
3
4.142
9
4.937
5
6.848
5
5.600
0
3.000
0

1.56004
2.52863
1.96396
2.73861
1.97294
2.54677
2.44241
2.22539
1.92226
2.47120
2.45919
2.70937
2.31405
2.53987
2.37246
3.56780
2.04819
2.79959
2.22427

.2715
7
.3000
9
.4285
7
.7319
3
.3543
5
.3134
9
.5207
2
.5745
9
.3346
2
.2953
6
.5366
4
.7241
1
.4090
7
.3102
9
.5177
1
.8919
5
.3565
4
.3346
1
.4973
6

6.386
2
4.852
2
1.677
4
1.918
8
4.953
7
3.601
2
3.098
9
3.434
3
6.166
9
4.953
6
1.833
0
2.007
1
3.915
7
3.320
8
3.062
9
3.036
4
6.122
2
4.932
5
1.959
0

7.492
6
6.049
2
3.465
4
5.081
2
6.401
1
4.853
3
5.264
7
5.899
0
7.530
1
6.132
1
4.071
8
5.135
8
5.584
3
4.559
8
5.222
8
6.838
6
7.574
7
6.267
5
4.041
0

4.00

10.00

.00

10.00

.00

6.00

.00

8.00

1.00

9.00

.00

9.00

.00

8.00

1.00

9.00

2.00

10.00

.00

10.00

.00

8.00

.00

9.00

.00

8.00

.00

9.00

.00

8.00

.00

10.00

2.00

10.00

.00

10.00

.00

7.00
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2.00
3.00
Tota
l

1
6
3
1
6
7

3.687
5
5.193
5
4.179
1

3.38071
2.56150
2.82266

.8451
8
.4600
6
.3448
4

1.886
0
4.254
0
3.490
6

5.489
0
6.133
1
4.867
6

Table 4.26. Pain Score Differences Between Anxiety Groups
Sum of Squares df Mean Square
F
S1PainPre Between Groups
139.880 2
69.940 15.457
Within Groups
307.697 68
4.525
Total
447.577 70
S1PainPost Between Groups
130.174 2
65.087 14.071
Within Groups
291.417 63
4.626
Total
421.591 65
S2PainPre Between Groups
108.523 2
54.261 11.621
Within Groups
312.848 67
4.669
Total
421.371 69
S2PainPost Between Groups
43.380 2
21.690 3.630
Within Groups
382.381 64
5.975
Total
425.761 66
S3PainPre Between Groups
103.049 2
51.524 7.886
Within Groups
437.751 67
6.534
Total
540.800 69
S3PainPost Between Groups
63.575 2
31.787 4.401
Within Groups
462.276 64
7.223
Total
525.851 66

.00

9.00

.00

10.00

.00

10.00

Sig.
.000

.000

.000

.032

.001

.016
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Figure 4.7. Pain Ratings for Low, Medium, and
High Anxiety Groups
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The distress scores of the three anxiety groups were also compared and significant
differences were found for the pre- and post-intervention distress scores for Session 1,
F(2,68) = 22.56, p < .000; F(2,60) = 5.97, p = .004. For the low anxiety group, the preintervention mean distress score was 2.68 and the post-intervention mean distress score
was 1.90, which shows a 0.78 point decrease for Session 1. The medium anxiety group
had a pre-intervention mean distress rating of 4.44 and a post-intervention mean distress
rating of 2.54, which is a 1.9 point reduction in distress. For the high anxiety group, the
mean pre-intervention distress rating was 6.55 and the mean post-intervention distress
rating was 4.28 showing a 2.27 point reduction in reported distress levels after the
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biofeedback training session. There were also statistically significant differences
between the three anxiety groups with pre- and post-intervention distress scores for
Session 2, F(2,67) = 13.17, p < .000; F(2,63) = 8.00, p = .001. The low anxiety group
had a pre-intervention mean distress rating of 3.23 and a post-intervention mean distress
rating of 1.75, which shows a 1.48 point decrease in distress scores. For the medium
anxiety group, the pre-intervention mean distress rating was 4.60 and the postintervention mean distress rating was 3.21 showing a 1.39 point decrease in distress. The
high anxiety group had a pre-intervention average distress score of 6.30 and a postintervention average distress score of 4.31, which is a 1.99 point decrease in reported
distress levels after the biofeedback training. Session 3 also had significant differences in
reported pre- and post-intervention distress ratings between the three anxiety groups,
F(2,67) = 10.75, p < .000; F(2,62) = 6.27, p = .003. The low anxiety group had a preintervention mean distress score of 3.48 and a post-intervention mean distress score of
2.05 showing a 1.43 point reduction in distress. The medium anxiety group had an
average pre-intervention distress rating of 4.13 and an average post-intervention distress
rating of 3.00, which shows a 1.13 point decrease. The high anxiety group had a preintervention mean distress rating of 6.67 and a post-intervention mean distress rating of
4.74, which is a 1.93 point decrease in reported distress levels after the biofeedback
session. The mean distress ratings of the three anxiety groups also had a “sawtooth”
pattern.

Table 4.27. Distress Scores of Low, Medium, and High Anxiety Groups
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Low (1),
Medium (2), and
Std.
High (3)
Deviatio Std.
Anxiety
Groups
N Mean
n
Error
S1DistressPre 1.00 2 2.681
.4670
2.19059
2
8
4
2.00 1 4.437
.6189
2.47572
6
5
3
3.00 3 6.545
.3230
1.85558
3
5
2
Tota 7 4.873
.3184
2.68291
l
1
2
0
S1DistressPos 1.00 2 1.904
.4874
2.23394
t
1
8
9
2.00 1 2.538
.6265
2.25889
3
5
0
3.00 2 4.275
.5107
2.75028
9
9
1
Tota 6 3.127
.3382
2.68504
l
3
0
8
S2DistressPre 1.00 2 3.227
.4920
2.30799
2
3
7
2.00 1 4.600
.6233
2.41424
5
0
5
3.00 3 6.303
.3521
2.02307
3
0
7
Tota 7 4.971
.3058
2.55928
l
0
4
9
S2DistressPos 1.00 2 1.750
.3898
1.74341
t
0
0
4
2.00 1 3.214
.6808
2.54735
4
3
1
3.00 3 4.312
.4222
2.38865
2
5
6

95%
Confidence
Interval for
Mean
Lowe
r
Upper
Boun Boun Minimu Maximu
d
d
m
m
1.710 3.653
.00
6.00
6
1
3.118 5.756
.00
9.00
3
7
5.887 7.203
3.00
10.00
5
4
4.238 5.508
.00
10.00
2
3
2.921
.8879
.00
6.00
6
1.173 3.903
.00
6.00
4
5
3.229 5.322
.00
10.00
7
0
2.450 3.803
.00
10.00
8
2
2.204 4.250
.00
8.00
0
6
3.263 5.937
.00
9.00
0
0
5.585 7.020
2.00
10.00
7
4
4.361 5.581
.00
10.00
2
7
2.565
.9341
.00
6.00
9
1.743 4.685
.00
8.00
5
1
3.451 5.173
.00
8.00
3
7
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Tota
l
S3DistressPre 1.00
2.00
3.00
Tota
l
S3DistressPos 1.00
t
2.00
3.00
Tota
l

6
6
2
1
1
6
3
3
7
0
1
9
1
5
3
1
6
5

3.303
0
3.476
2
4.125
0
6.666
7
5.128
6
2.052
6
3.000
0
4.741
9
3.553
8

2.48051
2.71328
3.30404
2.24537
3.00686
2.09427
3.18479
2.76849
2.91028

.3053
3
.5920
9
.8260
1
.3908
7
.3593
9
.4804
6
.8223
1
.4972
3
.3609
8

2.693
2
2.241
1
2.364
4
5.870
5
4.411
6
1.043
2
1.236
3
3.726
4
2.832
7

3.912
8
4.711
3
5.885
6
7.462
8
5.845
5
3.062
0
4.763
7
5.757
4
4.275
0

.00

8.00

.00

9.00

.00

9.00

2.00

10.00

.00

10.00

.00

7.00

.00

10.00

.00

10.00

.00

10.00

Table 4.28. Distress Score Differences Between Anxiety Groups
Sum of Squares df Mean Square
F
S1DistressPre Between Groups
200.967 2
100.484 22.559
Within Groups
302.892 68
4.454
Total
503.859 70
S1DistressPost Between Groups
74.151 2
37.075 5.967
Within Groups
372.833 60
6.214
Total
446.984 62
S2DistressPre Between Groups
127.510 2
63.755 13.166
Within Groups
324.433 67
4.842
Total
451.943 69
S2DistressPost Between Groups
80.957 2
40.479 7.995
Within Groups
318.982 63
5.063
Total
399.939 65
S3DistressPre Between Groups
151.521 2
75.761 10.747
Within Groups
472.321 67
7.050
Total
623.843 69
S3DistressPost Between Groups
91.179 2
45.589 6.269
Within Groups
450.883 62
7.272

Sig.
.000

.004

.000

.001

.000

.003
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Total

542.062 64

Figure 4.8. Distress Ratings for Low, Medium, and
High Anxiety Groups
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Somatization Groups
Finally, the dataset was divided into thirds based on somatization scores. The low
somatization group (n=21) had scores ranging from 0-8 (M = 6.05, SD = 1.72). The
medium somatization group (n=27) had scores in the middle from 9-15 (M = 12.30, SD =
2.16). The high somatization group (n=24) had the highest scores ranging from 16-24 (M
= 18.92, SD = 2.52).
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Table 4.29. Descriptive Statistics for Somatization Groups
Group

N

Range Mean (Standard Deviation)

Low Somatization

21 0-8

6.05 (1.72)

Medium Somatization 27 9-15

12.30 (2.16)

High Somatization

18.92 (2.52)

24 16-24

The Session 1 pre- and post-intervention pain scores had statistically significant
differences between the three somatization groups, F(2,69) = 7.30, p = .001; F(2,64) =
8.02, p = .001. The low somatization group had a pre-intervention mean pain rating of
4.00 and a post-intervention mean pain rating of 2.84, which is a 1.16 point decrease in
reported pain levels. The medium somatization group had an average pre-intervention
pain rating of 5.63 and an average post-intervention pain rating of 4.12 showing a 1.51
point decrease. The high somatization group had a pre-intervention mean pain rating of
6.67 and a post-intervention mean pain rating of 5.77, which shows a 0.9 point reduction
in reported pain levels. Session 2 pre-intervention pain ratings were significantly
different between groups F(2,68) = 4.13, p = .020. The post-intervention pain ratings
were different, however the difference is just shy (.001) of reaching statistical
significance, F(2,65) = 3.11, p = .051. The mean pre-intervention pain rating was 4.80
and post-intervention pain rating was 3.16 showing a 1.64 point decrease for the low
somatization group in Session 2. The medium somatization group had a pre-intervention
mean pain rating of 5.19 and a post-intervention mean pain rating of 3.72, which is a 1.47
point reduction in reported pain levels. The high somatization group had a preintervention mean pain rating of 6.71 and a post-intervention mean pain rating of 5.00
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which shows a 1.71 point decrease in reported pain levels after the biofeedback
intervention. The pre-intervention pain ratings for Session 3 were significantly different
between somatization groups, F(2,68) = 3.43, p = .038. The post-intervention pain
ratings were different but it was not statistically significant, F(2,65) = 1.83, p = .168.
The low somatization group had a mean pre-intervention pain rating of 4.65 and a mean
post-intervention pain rating of 3.45, which is a 1.20 point reduction in pain. The
medium somatization group had a pre-intervention average pain rating of 5.41 and a postintervention average pain rating of 4.12 showing a 1.29 point decrease. The high
somatization group’s pre-intervention mean pain score was 6.75 and their postintervention mean pain score was 5.09, which is a 1.66 point reduction in reported pain
levels after the biofeedback training. A familiar “sawtooth” pattern is seen with the pain
ratings of the three somatization groups.

Table 4.30. Pain Scores of Low, Medium, and High Somatization Groups
95%
Confidence
Low (1),
Interval for
Medium (2), and
Mean
Std.
High (3)
Deviatio Std. Lower Upper Minimu Maximu
Somatization
Groups
N Mean
n
Error Bound Bound
m
m
S1PainPre 1.00 2 4.000
.6761 2.589 5.410
3.09839
.00
9.00
1
0
2
6
4
2.00 2 5.629
.3703 4.868 6.390
1.92450
.00
8.00
7
6
7
3
9
3.00 2 6.666
.4067 5.825 7.508
1.99274
2.00
10.00
4
7
7
2
1
Tota 7 5.500
.2999 4.901 6.098
2.54536
.00
10.00
l
2
0
7
9
1
S1PainPos 1.00 1 2.842
.6410 1.495 4.188
2.79410
.00
8.00
t
9
1
1
4
8
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2.00
3.00
Tota
l
S2PainPre 1.00
2.00
3.00
Tota
l
S2PainPos 1.00
t
2.00
3.00
Tota
l
S3PainPre 1.00
2.00
3.00
Tota
l
S3PainPos 1.00
t
2.00
3.00
Tota
l

2
6
2
2
6
7
2
0
2
7
2
4
7
1
1
9
2
5
2
4
6
8
2
0
2
7
2
4
7
1
2
0
2
6
2
2
6
8

4.115
4
5.772
7
4.298
5
4.800
0
5.185
2
6.708
3
5.591
5
3.157
9
3.720
0
5.000
0
4.014
7
4.650
0
5.407
4
6.750
0
5.647
9
3.450
0
4.115
4
5.090
9
4.235
3

2.10384
2.22394
2.59379
2.98417
2.03880
2.17654
2.48755
3.02330
2.35443
2.22632
2.59444
3.37600
2.73523
1.98363
2.80865
3.50150
2.64313
2.22345
2.83958

.4126
0
.4741
4
.3168
8
.6672
8
.3923
7
.4442
8
.2952
2
.6935
9
.4708
9
.4544
5
.3146
2
.7549
0
.5264
0
.4049
1
.3333
3
.7829
6
.5183
6
.4740
4
.3443
5

3.265
6
4.786
7
3.665
8
3.403
4
4.378
7
5.789
3
5.002
8
1.700
7
2.748
1
4.059
9
3.386
7
3.070
0
4.325
4
5.912
4
4.983
1
1.811
2
3.047
8
4.105
1
3.548
0

4.965
1
6.758
8
4.931
2
6.196
6
5.991
7
7.627
4
6.180
3
4.615
1
4.691
9
5.940
1
4.642
7
6.230
0
6.489
4
7.587
6
6.312
7
5.088
8
5.183
0
6.076
7
4.922
6

.00

7.00

.00

9.00

.00

9.00

.00

9.00

1.00

9.00

2.00

10.00

.00

10.00

.00

9.00

.00

8.00

.00

9.00

.00

9.00

.00

10.00

.00

10.00

2.00

10.00

.00

10.00

.00

10.00

.00

8.00

.00

8.00

.00

10.00
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Table 4.31. Pain Score Differences Between Somatization Groups
Sum of Squares df Mean Square F Sig.
S1PainPre Between Groups
80.370 2
40.185 7.304 .001
Within Groups
379.630 69
5.502
Total
460.000 71
S1PainPost Between Groups
88.986 2
44.493 8.020 .001
Within Groups
355.044 64
5.548
Total
444.030 66
S2PainPre Between Groups
46.923 2
23.461 4.131 .020
Within Groups
386.232 68
5.680
Total
433.155 70
S2PainPost Between Groups
39.419 2
19.709 3.113 .051
Within Groups
411.566 65
6.332
Total
450.985 67
S3PainPre Between Groups
50.629 2
25.314 3.432 .038
Within Groups
501.569 68
7.376
Total
552.197 70
S3PainPost Between Groups
28.813 2
14.407 1.831 .168
Within Groups
511.422 65
7.868
Total
540.235 67
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Figure 4.9. Pain Ratings for Low, Medium, and
High Somatization Groups
10
9
Low
Somatization

8
Pain Rating

7

Medium
Somatization

6
5

High
Somatization

4
3

Total Group

2
1
0
S1 Pre S1 Post S2 Pre S2 Post S3 Pre S3 Post
Biofeedback Session

Session 1 pre- and post-intervention distress scores were different between the
somatization groups, however the differences were not statistically significant, F(2,69) =
2.87, p = .064; F(2,61) = 2.97, p = .059. For Session 1, the mean pre-intervention
distress score was 4.00 and the mean post-intervention distress score was 2.12, which is a
1.88 point decrease for the low somatization group. The medium somatization group had
a pre-intervention mean distress score of 4.81 and a post-intervention mean distress score
of 3.12 showing a 1.69 point decrease. The high somatization group had a preintervention mean distress rating of 5.88 and a post-intervention mean distress rating of
4.24, which is a 1.64 point reduction in reported distress scores. For Session 2, the preintervention distress ratings did not have significant differences between the groups,

126
however the post-intervention distress ratings were significantly different between the
three somatization groups, F(2,68) = 2.30, p = .108; F(2,64) = 7.45, p = .001. For the
low somatization group, the pre-intervention mean distress score was 4.75 and the postintervention mean distress score was 2.26 showing a 2.49 point decrease. The medium
somatization group had an average pre-intervention distress rating of 4.44 and an average
post-intervention distress rating 2.83, which is a 1.61 point reduction in distress scores.
The high somatization group’s pre-intervention mean distress rating was 5.92 and their
post-intervention mean distress rating was 4.83 showing a 1.09 point decrease in patientreported distress ratings. The Session 3 pre- and post-intervention distress ratings were
significantly different between the three somatization groups, F(2,68) = 3.50, p = .036;
F(2,63) = 3.28, p = .044. For the low somatization group, the mean pre-intervention
distress rating was 4.40 and the mean post-intervention distress rating was 2.95, which
shows a 1.45 point reduction. The medium somatization group had a pre-intervention
mean distress score of 4.63 and a post-intervention mean distress score of 3.00 showing a
1.63 point decrease. The high somatization group had a pre-intervention mean distress
rating of 6.46 and a post-intervention mean distress rating of 4.86, which is a 1.60 point
reduction in reported distress levels after the biofeedback training intervention. The
“sawtooth” pattern is seen again with the distress ratings of the three somatization groups.

Table 4.32. Distress Scores of Low, Medium, and High Somatization Groups
95%
Low (1),
Std.
Confidence
Medium (2), and
Deviatio Std.
Interval for Minimu Maximu
High (3)
Somatization
N Mean
n
Error
Mean
m
m
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l
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l
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Table 4.33. Distress Score Differences Between Somatization Groups
Sum of Squares df Mean Square F Sig.
S1DistressPre Between Groups
39.954 2
19.977 2.867 .064
Within Groups
480.699 69
6.967
Total
520.653 71
S1DistressPost Between Groups
42.709 2
21.355 2.973 .059
Within Groups
438.228 61
7.184
Total
480.938 63
S2DistressPre Between Groups
29.694 2
14.847 2.304 .108
Within Groups
438.250 68
6.445
Total
467.944 70
S2DistressPost Between Groups
81.560 2
40.780 7.449 .001
Within Groups
350.351 64
5.474
Total
431.910 66
S3DistressPre Between Groups
59.565 2
29.783 3.497 .036
Within Groups
579.055 68
8.516
Total
638.620 70
S3DistressPost Between Groups
52.219 2
26.110 3.280 .044
Within Groups
501.538 63
7.961
Total
553.758 65
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Figure 4.10. Distress Ratings for Low, Medium,
and High Somatization Groups
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Chapter 5: Discussion
Overview of Results
The overarching purpose of this study was to examine the outcomes of a newly
established biofeedback training program at a pain management center in the Midwest.
More specifically, the study was designed to examine six research questions focused on
the effects of a biofeedback training program on patients’ reported levels of pain and
distress, as well as catastrophizing, depression, anxiety, and somatization. It was
hypothesized that after three sessions of biofeedback, the patient scores on these six
variables would decrease. The results of this study present a somewhat complicated
picture of the effectiveness of the biofeedback training program for improving outcomes
related to these variables.
A significant reduction in self-reported pain and distress was found immediately
after the biofeedback session ended. However, these results were only short-lived
because pain and distress scores generally returned to the pre-session baseline by the
beginning of the next biofeedback session and the reductions in pain and distress were
not maintained between sessions. On average, patients reported a decrease of at least one
point when rating their pain after the biofeedback training intervention (1.21 for Session
1; 1.63 Session 2; and 1.50 for Session 3). There was a slightly greater reduction in
distress ratings than pain ratings after each session of biofeedback (i.e., distress ratings
decreased an average of 1.75 after Session 1, 1.67 after Session 2, and 1.74 after Session
3).
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Of the four symptom measures (catastrophizing, depression, anxiety, and
somatization), a statistically significant reduction was found only in the case of
catastrophizing scores. When comparing Session 1 and Session 3 catastrophizing, the
scores decreased 3.14 points on average (SD = 7.63), t(69) = 3.45, p = .001. This is an
important finding because catastrophizing influences one’s beliefs about his or her ability
to cope with pain and how much it interferes with his or her life. If catastrophizing
decreases, a patient with chronic pain may start to think about his or her pain differently
and increase his or her perceived control over the pain. This could be an important
benefit for long-term adjustment and improvement, a possibility that could be examined
in future studies.
There were statistically significant differences in pain and distress ratings between
catastrophizing groups. The high catastrophizing group consistently reported higher pain
ratings compared to the medium and low catastrophizing groups (see Figures 4.3 and
4.4). The high catastrophizing group reported higher pain and distress ratings than the
entire study sample as a whole. Also, the medium and low catastrophizing groups
reported lower pain and distress ratings than the total group sample. This is an important
observation because it shows an association between high levels of catastrophizing and
high levels of pain. However, from these findings, it cannot be determined whether
people with more pain have higher catastrophizing scores or if people with high
catastrophizing scores report more pain. Future studies using longitudinal designs would
have to be used to determine if there is a causal relationship between these variables.
There were also statistically significant differences between depression groups.
The low depression group consistently reported lower pain and distress ratings than the
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medium and high depression groups as well as the total sample. As shown in Figure 4.5,
the mean pain ratings for the low depression group were at least 1 point lower than the
total group. Figure 4.6 shows lower distress scores for the low depression group
compared to the total group. The differences between the distress ratings of the low
depression group and the total group increase with each biofeedback session. In addition,
both the pre- and post-intervention distress ratings for the low depression group continue
to decrease with each session. These results could be examined using a longitudinal
approach to see if this pattern continues with more biofeedback sessions.
The three anxiety groups also had statistically significant differences in pain and
distress ratings. The high anxiety group consistently reported higher pain and distress
ratings than the total group and the low and medium anxiety groups reported lower scores
than the total group. This is a comparable pattern to what was observed with the low,
medium, and high catastrophizing groups. This parallel is expected because
catastrophizing and anxiety are closely related concepts and can present some of the same
manifestations of symptoms. Also, initial catastrophizing scores and anxiety scores had
the strongest correlation among the four mental health variables, r(69) = 0.74, p < .001.
The three somatization groups had less statistically significant differences in pain
and distress ratings. However, a clinically relevant finding is that the high somatization
group had higher pain and distress scores than the total group. This relationship needs
further exploration through future studies.
Overall, the results finding an association between the high catastrophizing,
depression, and anxiety groups and higher levels of reported pain and distress highlight
the importance of individualized, comprehensive treatment for chronic pain. For
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example, perhaps people with high catastrophizing scores could benefit from therapy
interventions that target pain catastrophizing in addition to biofeedback training. The
IASP’s definition of pain acknowledges an emotional aspect of pain, and comprehensive
pain management should target both the physical and emotional aspects of living with
chronic pain.

Study Results in the Context of Existing Literature
The research literature suggests that biofeedback training can be an effective
intervention for people with migraine and tension-type headache (Blanchard and
Andrasik, 1987; Blanchard et al., 1980; Nestoriuc et al., 2008a; Nestoriuc et al., 2008b).
Recent meta-analyses that reviewed the research on biofeedback training with headache
found a medium to large effect size overall (Nestoriuc and Martin, 2007; Nestoriuc et al.,
2008). One major difference between this study and the studies from the meta-analyses
is the number of sessions. This study used data from patients who participated in as few
as three sessions of biofeedback. The meta-analysis by Nestoriuc and colleagues (2008)
used biofeedback studies with the number of sessions ranging from 3 to 24 (M = 10.8) for
migraine and 6 to 20 (M = 11.2) for tension-type headache (Nestoriuc et al., 2008). The
meta-analysis by Nestoriuc and colleagues (2008) that included 53 studies reported the
number of biofeedback sessions ranged from 6 to 20 (M = 10.8). This may provide
information on how many sessions are required to get the maximum benefit of pain
reduction of biofeedback training.
Out of the 72 patients from this study who completed three sessions or more,
there were 39 patients who completed four sessions of biofeedback. There was a mean
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1.67 decrease in pain ratings after Session 4 of biofeedback, t(38) = 5.992, p < .000.
Similarly to what was seen with pain ratings after Session 4 of biofeedback training,
Session 4 also had the largest decrease of patient reported distress ratings at an average of
2.46 points, t(38) = 6.088, p < .000. Although there were only 39 patients in the sample
who had four sessions of biofeedback, the study data indicate that the maximum benefit
for pain and distress relief is seen after four sessions of biofeedback. The research
literature suggests that even more improvement can be seen with a higher number of
biofeedback sessions.
Two pilot studies examined the effects of heart-rate variability biofeedback with
chronic neck pain (Hallman, et al., 2011) and fibromyalgia (Hassett, et al., 2007) and
found improvement in health and functioning as well as significant decreases in
depression and pain. The participants in both HRV biofeedback studies (Hallman et al.,
2001; Hassett, et al., 2007) had 10 weekly sessions of biofeedback training. Also, these
studies used more comprehensive assessment batteries that included measurements on
other biopsychosocial factors such as perceived health, physical functioning, and sleep.
The results of this dissertation study are not inconsistent with the current research
literature in that a significant reduction in pain and distress was observed immediately
after the biofeedback intervention. However, reductions in pain and distress were not
maintained over time. Also, this study only found a slight reduction in depression, not
one that was statistically significant. Aside from assessments of catastrophizing,
depression, anxiety, and somatization, health and functioning measures, like ones used in
other biofeedback studies, were not used in this study.
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Limitations
One major limitation of this study is the sample size. We collected information
from only 72 patient charts. Because the sample size is small, it would be hard to
generalize any findings to the general population. However, the study had patients with a
variety of pain diagnoses and may be more representative of a chronic pain population
than the general population, which includes healthy individuals. Also, because it was a
retrospective study, there was no control group used to compare those receiving the
intervention vs. those who did not. This makes it more difficult to determine
effectiveness of the biofeedback intervention because there was no control group to use
as a comparison.
Another limitation of this study was how the types of pain were coded in the
dataset. There were three types of pain in which chronic pain diagnoses were
categorized: musculoskeletal, neuropathic, and headache. These categories were
identified with the idea that the pain groups could be compared with one another for
follow-up analyses. However, many of the patients in this sample had more than one
type of pain therefore they were included in more than one pain category. An analysis of
variance based on pain type could not be executed because of the overlap between pain
groups.
Regular attendance and consistent practice were also limitations of this study. In
general, biofeedback sessions should be scheduled regularly (weekly or biweekly) so
patients can practice their skills. However, this was not always possible due to
cancelations and limited openings in the providers’ schedules. One of the
recommendations given to patients was to practice mindfulness and meditation skills
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twice per day using applications or websites at home. Many patients reported practicing
these skills at home and it strengthened their effectiveness. However, there were several
patients who did not practice at home and struggled to master the biofeedback skills. A
practice log could be used in future studies to encourage and track adherence to home
exercise plans.
In general, it can be difficult to obtain consistent and reliable data with a chronic
pain population. Chronic pain is often treatment resistant. Many of the patients involved
in the biofeedback training had also tried other interventions with some or no success.
There were many same day cancellations and no-shows because of the patient’s
condition. Also, patients with pain often rate their pain highly to communicate to their
providers that they are in excruciating pain at times, even if they do not appear to have
high pain levels at the time of the appointment. There were many patients who rated
their pain 10 on a scale of 0 to 10 at the beginning of the appointment but were able to
carry on a conversation and sit in a chair without visibly looking uncomfortable.
Similarly, many patients reported the same pain or distress ratings before and after
biofeedback training even though they made comments about how they felt more relaxed
after the biofeedback exercises. One woman talked about how she was able to see her
grandson for the first time in three years because she felt more confident in her ability to
survive the four-hour car ride because she had practiced the mindfulness skills she
learned in the biofeedback training program. Even though she described these changes in
her pain cognitions and behaviors, she still reported high ratings for all six variables on
the assessments. Using a numeric (0 to 10) rating scale as the only measure of pain and
distress may not capture the entire essence of chronic pain. To avoid these limitations,
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future researchers may want to focus on level of functioning, activities of daily living,
social relationships, and other behavioral anchors to gain a more comprehensive picture
of a patient’s condition and level of functioning. This would also allow an examination
of the relationship between these measures of functioning and subjective ratings of pain
such as that provided by the numeric (0 to 10) pain rating scale.
Another limitation in this study is that it examined data from a newly established
biofeedback program. The pain management center did not have a biofeedback program
before this one so many staff members and patients were not familiar with the program
and the concept of biofeedback in general. Patient and staff education was crucial in
implementing biofeedback as part of a comprehensive pain management plan. Overall,
the Relaxing Rhythms program was well liked by the patients because it offered guided
trainings and practice events that tested biofeedback skills through a computer game. It
was visually appealing yet challenging. The staff also liked the program because it
offered several options for guided trainings and the clinicians could choose a guided
training based on the skill the patient wanted to work on. For example, some patients
preferred to practice breathing exercises and others favored a body scan or guided
imagery. However, the Iom finger sensors sometimes stopped working and did not
accurately calculate the physiological measures used in the practice events. This was
frustrating because if the Iom sensors were not working then the patients could not test
their biofeedback skills in the practice events. A thermal biofeedback device was often
used in conjunction with the Iom sensors during the Relaxing Rhythms guided trainings.
Hand temperature was used as a physiological measure of biofeedback skills when the
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Iom sensors failed. However, patients seemed to prefer to play the computer games
through the Relaxing Rhythms program to practice their skills.

Future Directions
Because of the often-inconsistent patient report of pain and distress ratings and
the complicated nature of chronic pain, it would be beneficial for future studies to employ
a more comprehensive assessment battery that includes objective measurements of health
and functioning. A qualitative approach would also be valuable for assessing health and
functioning by eliciting verbal reports of the patient’s personal experience coping with
pain. Asking open-ended questions about a patient’s experience of pain might give more
information about the daily impact of living with chronic pain. As stated above, pain and
distress 0 to 10 rating scales may not fully capture the complexity of chronic pain and
also the success of an intervention like a biofeedback training program. Using the WongBaker FACES Pain Rating Scale (Wong-Baker FACES Foundation, 2016) may improve
the accuracy of patient report of pain and distress because there is a picture of a face
associated with each pain rating. Patients might be less likely to always rate their pain as
10/10 because the face shows someone crying and this does not match their experience
when they are asked to report pain levels. Also, a pain rating scale with definitions and
behavioral anchors could also help promote consistency and standardization of patient
report.
During the appointment, patients were able to practice deep breathing and
mindfulness skills using the Relaxing Rhythms biofeedback program. The practice
events gave instant confirmation that patients had steady breathing and heart rate, which
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reinforced their mindfulness skills. However, patients did not have this confirmation
when practicing at home. Future studies of using biofeedback as an intervention in the
chronic pain population may want to give patients a personal device, such as a thermal
biofeedback unit, to use when practicing at home to further reinforce their success with
biofeedback skills. There were several mindfulness applications recommended to
patients for at home practice. However, these apps only provided guided trainings and
not any biofeedback of the patient’s physiological state.

Recommendations for Practice
A heart rate variability biofeedback program, such as the one used in this study, is
a very cost effective intervention compared to other interventional treatment options.
The Wild Divine program is approximately $150 and includes the Relaxing Rhythms
software and Iom hardware. They have recently introduced an ear sensor to replace the
Iom finger sensors, which may increase the accuracy of measuring the body’s
physiological state. Although this study only showed immediate relief and not enduring
relief, it might still be a useful intervention for people who have chronic pain. Once the
patient learns how to recognize and influence physiological arousal, he or she can choose
to use these skills at any time. For example, a patient might use a breathing exercise to
manage a temporary pain flare-up or engage in guided imagery to help ease into sleep.
For many medications and interventional treatments for chronic pain, there is the
potential to overdose or overuse. However, this is not the case with biofeedback training.
The risk is very minimal and the biofeedback training can be discontinued abruptly
without a weaning plan. The nature of chronic pain is exactly that: chronic. Because of
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the complicated nature of pain, treatment success should be measured by a variety of
biopsychosocial factors, not solely on patient-reported pain ratings. Even temporary
reductions in pain can lead to more productive days, better relationships, and increased
socialization for people living with chronic pain. Chronic pain does not require constant
misery.
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